var title_f16_3_16432="Types of tenaculum";
var content_f16_3_16432=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F77725&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F77725&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Tenaculums",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 404px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Beirer tenaculum. (B) Single tooth tenaculum.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William J Mann, Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_3_16432=[""].join("\n");
var outline_f16_3_16432=null;
var title_f16_3_16433="Esophageal parakeratosis";
var content_f16_3_16433=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F70116&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F70116&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Esophageal parakeratosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 291px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoscopic view of esophageal parakeratosis showing a characteristic whitish, membranous plaque.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Daniel Wild, MD, and Moises Guelrud, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_3_16433=[""].join("\n");
var outline_f16_3_16433=null;
var title_f16_3_16434="Two thumb technique";
var content_f16_3_16434=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F77050&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F77050&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Chest compression for infant resuscitation: Two thumb technique",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 388px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The thorax is encircled with the hands and cardiac compressions are performed with both thumbs. The compression site is approximately one finger's breadth below the intermammary line. The area over the xiphoid process should be avoided to prevent injury to the liver, spleen, or stomach.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_3_16434=[""].join("\n");
var outline_f16_3_16434=null;
var title_f16_3_16435="Basic principles in the laboratory evaluation of adrenocortical function";
var content_f16_3_16435=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Basic principles in the laboratory evaluation of adrenocortical function",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/3/16435/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/3/16435/contributors\">",
"     Lynnette K Nieman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/3/16435/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/3/16435/contributors\">",
"     Andre Lacroix, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/3/16435/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/3/16435/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/3/16435/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The adrenal cortex consists of three functional zones [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16435/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The zona glomerulosa, which secretes aldosterone and is primarily under the control of the renin-angiotensin system",
"     </li>",
"     <li>",
"      The zona fasciculata, which secretes cortisol and is regulated by the corticotropin-releasing hormone (CRH)-corticotropin (ACTH) system",
"     </li>",
"     <li>",
"      The zona reticularis, which secretes dehydroepiandrosterone (DHEA), DHEA sulfate, and small amounts of testosterone and other 19-carbon steroids, and is under the control of ACTH and perhaps other proopiomelanocortin (POMC)-derived peptides",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Consequently, evaluation of adrenal function requires measurement of the relevant adrenal hormones and their metabolites and sometimes of the secretagogues that regulate their secretion.",
"   </p>",
"   <p>",
"    This topic will review the basic principles that should be considered when using these tests to determine if a patient has some abnormality in adrenal hormone synthesis. The specific diagnostic approach to disorders such as Cushing's syndrome, adrenal insufficiency, and hyperaldosteronism are discussed separately.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     REFERENCE RANGES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reference ranges referred to in the discussion of various assays are intended only as general guidelines. Each laboratory has its own assay procedures and normal or reference ranges. Reference ranges should, in general, be viewed with some skepticism with regard to how they were established, particularly if they deviate significantly from those listed in the discussions of the individual tests.",
"   </p>",
"   <p>",
"    Salivary and circulating hormone levels may have a diurnal rhythm. Time-specific normal ranges should be sought for these tests and test strategies should be planned with this in mind. As an example, measurement of late evening, but not early morning, serum or salivary cortisol levels is useful for the diagnosis of Cushing's syndrome, whereas measurement of early morning, but not late evening, serum or salivary cortisol levels is useful for the diagnosis of adrenal insufficiency. Clinicians should verify whether their patients have unusual sleep hour patterns (eg, night shift work).",
"   </p>",
"   <p>",
"    In addition, other tests that evaluate the function of systems that are regulated by nonhormonal factors may not have broadly applicable \"normal\" values. This problem is illustrated by the renin-angiotensin-aldosterone system. The activity of this system is regulated in part by the effective arterial blood volume, which is determined in normal subjects by sodium intake. Thus, interpretation of measurements of plasma renin activity and serum aldosterone requires knowledge of the level of sodium intake, which, in the steady state, can be estimated from 24-hour urinary sodium excretion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/20/2376?source=see_link\">",
"     \"Chapter 6C: Aldosterone\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/35/7736?source=see_link\">",
"     \"Assays of the renin-angiotensin-aldosterone system in adrenal disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     LABORATORY AND PATIENT ERRORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A clinician is only as good as the reference laboratory. Because the symptoms and signs of adrenocortical disorders are often subtle and nonspecific, assessment of basal hormone secretion may not establish the diagnosis, and even the most reliable laboratory is capable of occasional error. Regrettably, some reference laboratories consistently provide erroneous results for one or more of the assays used for evaluation of the hypothalamic-pituitary-adrenal (HPA) axis. The assays",
"    <strong>",
"     most subject to error",
"    </strong>",
"    are the serum and salivary cortisol assays (especially at low values), and the urinary 17-hydroxycorticosteroid (17-OHCS) colorimetric assay (which is not often used).",
"   </p>",
"   <p>",
"    The choice of assay can affect the results. For example, urine cortisol can be measured commercially by liquid",
"    <span class=\"nowrap\">",
"     chromatography/mass",
"    </span>",
"    spectrometry, based on its structure, or by an antibody-based assay. The structurally-based assays have little cross-reactivity with other endogenous or exogenous glucocorticoids. By contrast, other steroids may cross-react in the antibody-based assays and contribute to the higher reference ranges for those assays. In addition to errors in the laboratory, patients can inadvertently contribute to inaccurate tests. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/22/41319?source=see_link\">",
"     \"Measurement of urinary excretion of endogenous and exogenous glucocorticoids\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/19/40246?source=see_link\">",
"     \"Measurement of ACTH, CRH, and other hypothalamic and pituitary peptides\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Detecting inconsistencies in lab data",
"    </span>",
"    &nbsp;&mdash;&nbsp;One cannot detect all laboratory errors, but there are some useful principles for evaluating the results. Most important is awareness that any result may be incorrect, particularly when it conflicts with otherwise consistent data.",
"   </p>",
"   <p>",
"    As an example, if urinary cortisol is elevated, one would expect that urinary 17-OCHS and the evening cortisol in serum or saliva would be elevated as well. With regard to these three assays, serum or urinary cortisol is most likely to be correct and urinary 17-OHCS is most likely to be incorrect. Conflicting results should be checked and repeated in the same or another laboratory. A diagnosis should not be made in the face of inconsistent laboratory data.",
"   </p>",
"   <p>",
"    There is an additional potential error when applying these principles to urinary cortisol excretion in states of marked hypercortisolism. When the serum cortisol concentration exceeds the normal binding capacity of cortisol-binding globulin (CBG) of about 25",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (690",
"    <span class=\"nowrap\">",
"     nmol/L),",
"    </span>",
"    there will be a proportionately greater rise in cortisol excretion since more cortisol in serum is unbound.",
"   </p>",
"   <p>",
"    The above relationships between urinary and serum cortisol presumes that the CBG concentration is normal. Low CBG concentrations, as may be seen in critical illness or nephrotic syndrome, result in a lower than expected cortisol value [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16435/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Conversely, high CBG concentrations, as seen with oral estrogen administration, increase serum cortisol concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16435/abstract/3\">",
"     3",
"    </a>",
"    ]. In the latter case, a 24-hour urinary free and salivary cortisol better reflects adrenal function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Patient errors",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a few major sources of patient errors:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Failure to take prescribed medications or to take them on the proper schedule",
"     </li>",
"     <li>",
"      Failure to inform the clinician of other medications (such as exogenous glucocorticoid-containing drugs, creams or injections) that may interfere with the diagnostic tests, the hormonal assays, or both",
"     </li>",
"     <li>",
"      Failure to collect 24-hour urine specimens properly",
"     </li>",
"     <li>",
"      Failure to collect salivary cortisol properly, resulting in contamination of the specimen with cortisol-containing topical agents",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The first two must be dealt with by diligence on the part of both clinician and patient, particularly when tests are increasingly being conducted on an ambulatory basis. Improper 24-hour urine collections can be minimized by explaining to the patient in detail how the samples should be collected, emphasizing how important they are to the diagnosis, and making the patient (either in or out of hospital) fully responsible for their accuracy. The patient should then be requested to repeat exactly how the urine is to be collected to be certain that the instructions are understood. It is helpful to have printed instructions to which the patient can refer. (See",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?20/41/21151?source=see_link\">",
"     \"Patient information: Collection of a 24-hour urine specimen (Beyond the Basics)\"",
"    </a>",
"    .) Additionally, the completeness of the collection may be assessed by measuring the volume and the creatinine. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/22/41319?source=see_link\">",
"     \"Measurement of urinary excretion of endogenous and exogenous glucocorticoids\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evaluation of adrenal function requires measurement of the relevant adrenal hormones, their metabolites, and sometimes the secretagogues that regulate their secretion. Correct interpretation of results depends upon a number of factors including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Source and accuracy of normative data for any given assay",
"     </li>",
"     <li>",
"      Appropriate timing of sample collection (eg, cortisol secretion has a diurnal rhythm)",
"     </li>",
"     <li>",
"      Identifying laboratory error, and patient errors in medication compliance",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      sample collection",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Specific assays are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/35/7736?source=see_link\">",
"     \"Assays of the renin-angiotensin-aldosterone system in adrenal disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/60/21445?source=see_link\">",
"     \"Measurement of adrenal androgens\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/8/132?source=see_link\">",
"     \"Measurement of cortisol in serum and saliva\"",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16435/abstract/1\">",
"      Miller WL. Steroidogenic enzymes. Endocr Dev 2008; 13:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16435/abstract/2\">",
"      Arlt W, Stewart PM. Adrenal corticosteroid biosynthesis, metabolism, and action. Endocrinol Metab Clin North Am 2005; 34:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16435/abstract/3\">",
"      Klose M, Lange M, Rasmussen AK, et al. Factors influencing the adrenocorticotropin test: role of contemporary cortisol assays, body composition, and oral contraceptive agents. J Clin Endocrinol Metab 2007; 92:1326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16435/abstract/4\">",
"      Hamrahian AH, Oseni TS, Arafah BM. Measurements of serum free cortisol in critically ill patients. N Engl J Med 2004; 350:1629.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 172 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-7ADB670DEC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_3_16435=[""].join("\n");
var outline_f16_3_16435=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H6\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      REFERENCE RANGES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      LABORATORY AND PATIENT ERRORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Detecting inconsistencies in lab data",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Patient errors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/35/7736?source=related_link\">",
"      Assays of the renin-angiotensin-aldosterone system in adrenal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/20/2376?source=related_link\">",
"      Chapter 6C: Aldosterone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/19/40246?source=related_link\">",
"      Measurement of ACTH, CRH, and other hypothalamic and pituitary peptides",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/60/21445?source=related_link\">",
"      Measurement of adrenal androgens",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/8/132?source=related_link\">",
"      Measurement of cortisol in serum and saliva",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/22/41319?source=related_link\">",
"      Measurement of urinary excretion of endogenous and exogenous glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?20/41/21151?source=related_link\">",
"      Patient information: Collection of a 24-hour urine specimen (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_3_16436="Prucalopride: Patient drug information";
var content_f16_3_16436=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Prucalopride: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/10/18596?source=see_link\">",
"     see \"Prucalopride: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F13761703\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Resotran&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F13831245\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3656467",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat hard stools (constipation) in women who have had hard stools for a long time.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F13831244\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3656468",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to prucalopride or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3656472",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Crohn's disease, a large colon, hole in the GI (gastrointestinal) tract, bowel block, ulcerative colitis, or are on dialysis.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701070",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are on a low-galactose or lactose-free diet.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F13831249\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697300",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have lung disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4128402",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you drink grapefruit juice or eat grapefruit often, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697801",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may not be alert. Avoid driving and doing other tasks or actions until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3656474",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Birth control pills may not work if you have very loose stools (diarrhea). Use other birth control if this happens.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F13831250\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F13831251\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698607",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Black, tarry, or bloody stools.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F13831247\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F13831248\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F13831252\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F13831253\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 83369 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.77.166.39-6D34BE7A96-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_3_16436=[""].join("\n");
var outline_f16_3_16436=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13761703\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13831245\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13831244\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13831249\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13831250\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13831251\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13831247\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13831248\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13831252\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13831253\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?18/10/18596?source=related_link\">",
"      Prucalopride: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_3_16437="Glatiramer acetate: Drug information";
var content_f16_3_16437=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Glatiramer acetate: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?31/23/32116?source=see_link\">",
"    see \"Glatiramer acetate: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F176076\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Copaxone&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F176077\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Copaxone&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F176098\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Biological, Miscellaneous",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F176078\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Multiple sclerosis (relapsing-remitting): SubQ: 20 mg daily",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F176079\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15896358\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15896359\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F176063\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Copaxone&reg;: 20 mg/mL (1 mL) [contains mannitol]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F176050\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F176065\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For SubQ administration in the arms, abdomen, hips, or thighs; rotate injection sites to prevent lipoatrophy. Bring to room temperature prior to use.  Visually inspect the solution; discard if solution is cloudy or contains any particulate matter.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F176064\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of relapsing-remitting type multiple sclerosis, including patients with a first clinical episode with MRI features consistent with multiple sclerosis",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F176105\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Copaxone&reg; may be confused with Compazine",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F176096\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Vasodilation (20%), chest pain (13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Pain (20%), anxiety (13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (19%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site reactions: Inflammation (49%), erythema (43%), pain (40%), pruritus (27%), mass (27%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness (22%), back pain (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Dyspnea (14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Infection (30%), flu-like syndrome (14%), diaphoresis (15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Edema (8%; includes peripheral and facial), palpitation (7%), tachycardia (5%), syncope (3%), hypertension (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fever (6%), migraine (4%), chills (3%), nervousness (2%), speech disorder (2%), abnormal dreams (1%), emotional lability (1%), stupor (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Bruising (8%), pruritus (5%), erythema (4%), urticaria (3%), skin nodule (2%), eczema (1%), pustular rash (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Amenorrhea (1%), impotence (1%), menorrhagia (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Vomiting (7%), gastroenteritis (6%), weight gain (3%), dysphagia (2%), dental caries (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Urinary urgency (5%), vaginal moniliasis (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site reactions: Hemorrhage (5%), hypersensitivity (4%),  fibrosis (2%), lipoatrophy (2%), abscess (1%), edema (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Neck pain (8%), tremor (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Diplopia (3%), visual field defect (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Rhinitis (7%), bronchitis (6%), cough (6%), laryngismus (5%), hyperventilation (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Lymphadenopathy (7%), hypersensitivity (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Allergic reaction, anaphylactoid reaction, anemia, angina, angioedema, aphasia, appetite increased, arrhythmia, arthritis, asthma, atrial fibrillation, blindness, bradycardia, carcinoma (breast, bladder, lung, ovarian), cardiomyopathy, cataract, cervical cancer, cholecystitis, cholelithiasis, cirrhosis, CNS neoplasm, colitis, corneal ulcer, Cushing's syndrome, dermatitis, dry eyes, dry skin, esophagitis, gastrointestinal carcinoma, gastrointestinal hemorrhage, gastrointestinal ulcer, glaucoma, gout, hallucination, heart failure, hepatitis, hepatomegaly, hypercholesterolemia, hypotension, injection site necrosis, leukemia, leukopenia, libido decreased, lupus erythematosus, lymphoma-like reaction, mania, meningitis, MI, mouth ulceration, neuralgia, optic neuritis, orthostatic hypotension, pancreatitis, pancytopenia, pericardial effusion, peripheral vascular disease, photophobia, pneumonia, priapism, pulmonary embolism, pyelonephritis, renal failure, seizures, sepsis, skin cancer, spasm, splenomegaly, stomatitis, stroke, thrombocytopenia, thrombophlebitis, thrombosis, urethritis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F176068\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to glatiramer acetate, mannitol, or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F176054\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Chest pain:  May or may not occur with the immediate postinjection reaction; described as a transient pain usually resolving in a few minutes; often unassociated with other symptoms.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Lipoatrophy:  May occur locally at injection site and may not resolve; advise patient to follow proper injection technique and rotate site daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Immune response:  Although there has not been a systematic evaluation of glatiramer&rsquo;s potential to affect other  immune functions, it may interfere with recognition of foreign antigens undermining the body&rsquo;s tumor surveillance and defense system against infection.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Systemic reactions: Immediate postinjection systemic reactions occur in a substantial percentage of patients (~16% in studies); symptoms (anxiety, chest pain, dysphagia, flushing, palpitations, urticaria) may begin within minutes of injection and are usually self-limited and transient. These symptoms generally occur several months after initiation of glatiramer.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Safety and efficacy has not been established in patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Safety and efficacy has not been established in the elderly.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Safety and efficacy have not been established in children.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Administration: For SubQ use only,",
"     <b>",
"      not for I.V. administration.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Antigenic: Glatiramer acetate is antigenic, and may possibly lead to the induction of untoward host responses. Glatiramer acetate-reactive antibodies (IgG subtype) form in most patients.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299405\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6220654\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F176060\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F176070\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed in animal studies. There are no adequate and well-controlled studies in pregnant women. Use in pregnancy only if clearly necessary.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F176081\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F16265835\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if glatiramer acetate is excreted in breast milk. The manufacturer recommends that caution be exercised when administering glatiramer acetate to nursing women.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F176069\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Kit",
"     </b>",
"     (Copaxone Subcutaneous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg/mL (1): $5525.39",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F176071\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Copaxone (AR, AT, AU, BE, BG, BR, CH, CO, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HN, HU, IE, IL, IT, NL, NO, NZ, PE, PL, PY, RU, SE, TR, TW, UY)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F176053\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Glatiramer is a mixture of random polymers of four amino acids; L-alanine, L-glutamic acid, L-lysine, and L-tyrosine, the resulting mixture is antigenically similar to myelin basic protein, which is an important component of the myelin sheath of nerves; glatiramer is thought to induce and activate T-lymphocyte suppressor cells specific for a myelin antigen, it is also proposed that glatiramer interferes with the antigen-presenting function of certain immune cells opposing pathogenic T-cell function",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F176067\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Small amounts of intact and partial hydrolyzed drug enter lymphatic circulation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: SubQ: Large percentage hydrolyzed locally",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Bornstein MB, Miller A, Slagle S, et al, &ldquo;A Pilot Trial of Cop 1 in Exacerbating-Remitting Multiple Sclerosis,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1987, 317(7):408-14.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/3/16437/abstract-text/3302705/pubmed\" id=\"3302705\" target=\"_blank\">",
"        3302705",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cohen JA, Rovaris M, Goodman AD, et al, &ldquo;Randomized, Double-Blind, Dose-Comparison Study of Glatiramer Acetate in Relapsing-Remitting MS,&rdquo;",
"      <i>",
"       Neurology",
"      </i>",
"      , 2007, 68(12):939-44.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/3/16437/abstract-text/17372130/pubmed\" id=\"17372130\" target=\"_blank\">",
"        17372130",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Comi G, Filippi M, Wolinsky JS, et al, &ldquo;European/Canadian Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of the Effects of Glatiramer Acetate on Magnetic Resonance Imaging-Measured Disease Activity and Burden in Patients With Relapsing Multiple Sclerosis,&rdquo;",
"      <i>",
"       Ann Neurol",
"      </i>",
"      , 2001, 49(3):290-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/3/16437/abstract-text/11261502/pubmed\" id=\"11261502\" target=\"_blank\">",
"        11261502",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Johnson KP, Brooks BR, Cohen JA, et al, &ldquo;Copolymer 1 Reduced Relapse Rate and Improves Disability in Relapsin-Remitting Multiple Sclerosis: Results of a Phase III Multicenter, Double-Blind, Placebo-Controlled Trial,&rdquo;",
"      <i>",
"       Neurology",
"      </i>",
"      , 1995, 45(7):1268-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/3/16437/abstract-text/7617181/pubmed\" id=\"7617181\" target=\"_blank\">",
"        7617181",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Johnson KP, Brooks BR, Cohen JA, et al, &ldquo;Extended Use of Glatiramer Acetate (Copaxone) is Well Tolerated and Maintains Its Clinical Effect on Multiple Sclerosis Relapse Rate and Degree of Disability,&rdquo;",
"      <i>",
"       Neurology",
"      </i>",
"      , 1998, 50(3):701-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/3/16437/abstract-text/9521260/pubmed\" id=\"9521260\" target=\"_blank\">",
"        9521260",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Noseworthy JH, Lucchinetti C, Rodriguez M, and Weinshenker BG, &ldquo;Multiple Sclerosis,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2000, 343(13):938-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/3/16437/abstract-text/11006371/pubmed\" id=\"11006371\" target=\"_blank\">",
"        11006371",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8490 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-F7325097AE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_3_16437=[""].join("\n");
var outline_f16_3_16437=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176076\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176077\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176098\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176078\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176079\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15896358\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15896359\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176063\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176050\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176065\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176064\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176105\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176096\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176068\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176054\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299405\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6220654\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176060\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176070\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176081\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16265835\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176069\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176071\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176053\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176067\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8490\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8490|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?31/23/32116?source=related_link\">",
"      Glatiramer acetate: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_3_16438="Signal averaged ECG in early repolarization";
var content_f16_3_16438=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F83890&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F83890&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 643px\">",
"   <div class=\"ttl\">",
"    Signal averaged ECG in early repolarization",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 623px; height: 372px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Signal averaged ECG in a patient with ER demonstrating normal parameters (filtered QRS duration 124 ms, duration of high frequency low amplitude signal less than 40 microvolts of 37 ms, and root mean square voltage in the terminal 40 ms of 19 microvolts).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_3_16438=[""].join("\n");
var outline_f16_3_16438=null;
var title_f16_3_16439="Monkeypox";
var content_f16_3_16439=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Monkeypox",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/3/16439/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/3/16439/contributors\">",
"     Stuart N Isaacs, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/3/16439/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/3/16439/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/3/16439/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/3/16439/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/3/16439/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Monkeypox is a viral zoonotic infection that results in a rash similar to smallpox. However, the person-to-person spread and the mortality from a monkeypox infection are significantly lower than for smallpox. Clinically, these two viral infections are difficult to distinguish, raising concerns that monkeypox could be used for bioterrorism [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16439/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/61/35797?source=see_link\">",
"     \"The epidemiology, pathogenesis, and clinical manifestations of smallpox\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/46/22247?source=see_link\">",
"     \"Identifying and managing casualties of biological terrorism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic will review the virology, epidemiology, clinical manifestations, diagnosis and treatment of monkeypox.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     VIROLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Monkeypox, an orthopoxvirus, was first isolated in the late 1950s from a colony of sick monkeys. The virus is in the same genus as variola (causative agent of smallpox) and vaccinia viruses (the virus used in",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/24/18823?source=see_link\">",
"     smallpox vaccine",
"    </a>",
"    ). Electron microscopy of cells infected with monkeypox virus shows a brick-like virion, indistinguishable from the virions of variola or vaccinia viruses (",
"    <a class=\"graphic graphic_picture graphicRef56100 \" href=\"UTD.htm?13/23/13683\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Two distinct strains of monkeypox exist in different geographic regions of Africa, as suggested by epidemiologic, animal, and molecular evidence [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16439/abstract/2\">",
"     2",
"    </a>",
"    ]. In comparison to strains isolated from Central Africa, monkeypox from Western Africa is less virulent and lacks a number of genes present in the other viral strain [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16439/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is believed that monkeypox virus has infected humans for thousands of years in sub-Saharan Africa [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16439/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Monkeypox was first identified as a cause of disease in humans in the 1970s in the Democratic Republic of the Congo (formerly the Republic of Zaire) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16439/abstract/1,4-7\">",
"     1,4-7",
"    </a>",
"    ]. Following its recognition as a human pathogen, 59 cases of human monkeypox were reported between 1970 and 1980, with a mortality rate of 17 percent. All of these cases occurred in the rain forests of western and central Africa among individuals exposed to small forest animals (eg, rodents, squirrels and monkeys).",
"   </p>",
"   <p>",
"    The first outbreak of monkeypox in the Western Hemisphere occurred in the United States between May 15 and June 20, 2003 [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16439/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'United States'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5779046\">",
"    <span class=\"h2\">",
"     Transmission",
"    </span>",
"    &nbsp;&mdash;&nbsp;The virus is acquired through contact with the animal's blood or through a bite. Monkeys and humans are incidental hosts; the reservoir remains unknown, but is likely to be rodents. Infected animals from Western Africa were accidentally imported into the United States; this led to the first human monkeypox infections in the western hemisphere. In general, transmissibility from person-to-person is very low [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16439/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based on findings during the US outbreak, the route of infection and extent of exposure (eg, bite wound versus touching an infected animal) can influence the severity of clinical manifestations of monkeypox infection. For example, one study categorized exposures to a prairie dog as noninvasive (eg, the person touched an infected animal, cleaned an infected animal's cage) or \"complex\" (eg, invasive bite or scratch from an ill prairie dog) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16439/abstract/12\">",
"     12",
"    </a>",
"    ]. Patients with complex exposures were more likely than patients with noninvasive exposures to develop signs of systemic illness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5779060\">",
"    <span class=\"h2\">",
"     Eradication of smallpox and impact on monkeypox",
"    </span>",
"    &nbsp;&mdash;&nbsp;After the eradication of smallpox and the discontinuation of smallpox immunization (ie, vaccinia virus vaccine), the World Health Organization (WHO) monitored subsequent human monkeypox activity. The WHO was concerned that elimination of the vaccinia virus vaccine, which also protects against monkeypox, would lead to increased susceptibility of the population and the possibility of an increased incidence of monkeypox infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Africa",
"    </span>",
"    &nbsp;&mdash;&nbsp;From 1996 to 1998, an outbreak of febrile illness with associated pustular lesions occurred among about 100 persons with reports of secondary attack rates of 80 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16439/abstract/4,7\">",
"     4,7",
"    </a>",
"    ]. A concurrent chickenpox outbreak may have resulted in misclassification of cases and likely explained the high secondary attack rates. Nevertheless, this outbreak created concern that monkeypox had mutated to become more like smallpox [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16439/abstract/4,7\">",
"     4,7",
"    </a>",
"    ]. However, sequence analyses of monkeypox from persons with active cases indicated no significant genetic changes [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16439/abstract/11,13\">",
"     11,13",
"    </a>",
"    ]. The overall low mortality during this outbreak of less than 5 percent was another indication that monkeypox had not mutated into smallpox [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16439/abstract/7,11\">",
"     7,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A subsequent population-based surveillance study from 2005 to 2007 confirmed a 20-fold increase in incidence of monkeypox infection compared with that seen in the 1980s in the Democratic Republic of Congo [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16439/abstract/14\">",
"     14",
"    </a>",
"    ]. From 2005 to 2007, 760 laboratory-confirmed human monkeypox cases were identified [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16439/abstract/14\">",
"     14",
"    </a>",
"    ]. The study confirmed prior concerns of increased human cases of monkeypox due to the lack of prior",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/24/18823?source=see_link\">",
"     smallpox vaccination",
"    </a>",
"    ; persons with a history of smallpox immunization had a fivefold lower risk of monkeypox infection than unvaccinated persons. Other factors associated with an increased risk of infection included living in forested areas, male gender, and age &lt;15 years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     United States",
"    </span>",
"    &nbsp;&mdash;&nbsp;An outbreak of 71 cases of human monkeypox in six states was investigated by the Centers for Disease Control and Prevention (CDC); 35 cases were laboratory confirmed [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16439/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. Prior to this cluster of cases, monkeypox had not been previously found in the Western hemisphere.",
"   </p>",
"   <p>",
"    The investigation demonstrated that the onset of a febrile illness, with subsequent appearance of a pustular rash, had developed in patients who had recently purchased pet prairie dogs. The prairie dogs appeared to have acquired the virus from African rodents when the two species were housed at a distribution center in Illinois.",
"   </p>",
"   <p>",
"    Monkeypox infection was confirmed by DNA sequences obtained from skin lesions from 9 of 10 patients from Illinois, Indiana, and Wisconsin and in lymph node tissue of one pet prairie dog that died [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16439/abstract/8\">",
"     8",
"    </a>",
"    ]. Most of the human cases had direct exposure to animals [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16439/abstract/15\">",
"     15",
"    </a>",
"    ], although person-to-person transmission could not be excluded. Of the cases reported in Wisconsin, the veterinary staff who were exposed to an outbreak-associated prairie dog were at particularly high risk, with an attack rate of 23 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16439/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    During this outbreak, monkeypox appeared to have a very low rate of person-to-person transmission. In one study of 57 healthcare workers who were exposed to patients with monkeypox, none reported signs and symptoms of disease [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16439/abstract/17\">",
"     17",
"    </a>",
"    ]. Only one had laboratory evidence of recent orthopoxvirus infection, which was probably secondary to prior",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/24/18823?source=see_link\">",
"     smallpox vaccination",
"    </a>",
"    . By contrast, secondary attack rates for smallpox can be as high as 70 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16439/abstract/5,18\">",
"     5,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because of this outbreak, the transportation, sale, or release into the wild of prairie dogs and animals from Africa (including tree squirrels, rope squirrels, dormice, brush-tailed porcupines, and striped mice in addition to Gambian giant rats) was subsequently prohibited by the CDC and the United States Food and Drug Administration (FDA) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16439/abstract/10\">",
"     10",
"    </a>",
"    ]. There have been no other US outbreaks since the time of this prohibition. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3086988\">",
"    <span class=\"h1\">",
"     INCUBATION PERIOD",
"    </span>",
"    &nbsp;&mdash;&nbsp;The US outbreak described above allowed estimation of time from exposure to onset of symptoms. Approximately half of the patients reported a scratch, bite, or petting of an infected animal [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16439/abstract/19\">",
"     19",
"    </a>",
"    ]. For 29 patients, the estimated incubation time from exposure to illness was 12 days. Persons with a history of an animal bite or scratch may have a shorter incubation period than those with tactile exposures (13 versus 9 days, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16439/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based largely on seroepidemiological studies in Africa, the majority of monkeypox infections are asymptomatic. In symptomatic individuals, monkeypox causes a systemic illness including fevers, chills, and myalgias, with a characteristic rash that is important to differentiate from that of smallpox. The clinical illness can also differ by viral strain. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3087483\">",
"    <span class=\"h2\">",
"     Outbreaks in Africa",
"    </span>",
"    &nbsp;&mdash;&nbsp;In Africa, the monkeypox rash starts on the trunk and then spreads peripherally to involve the palms and soles of the feet. Lesions can also involve the mucous membranes and usually range from 0.5 to 1 centimeter in size. The rash usually begins as macules and papules; the rash then progresses over a two to four week period to vesicles, pustules, followed by umbilication, scabbing, and desquamation. Some patients develop only a localized rash on their hands associated with direct contact with the infected animal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3087007\">",
"    <span class=\"h2\">",
"     United States outbreak",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although comprehensive clinical information is limited on monkeypox in Africa, the 2003 US outbreak allowed further characterization of the illness in 34 of 37 subjects for whom medical records were available [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16439/abstract/19\">",
"     19",
"    </a>",
"    ]. The predominant signs and symptoms were:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Rash (97 percent)",
"     </li>",
"     <li>",
"      Fever (85 percent)",
"     </li>",
"     <li>",
"      Chills (71 percent)",
"     </li>",
"     <li>",
"      Lymphadenopathy (71 percent)",
"     </li>",
"     <li>",
"      Headache (65 percent)",
"     </li>",
"     <li>",
"      Myalgias (56 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The onset of fever preceded the rash by approximately two days, but the median duration of fever was shorter than the rash (8 and 12 days, respectively). The following clinical pictures of the initial case identified in the United States were taken at the Marshfield Clinic in Wisconsin (",
"    <a class=\"graphic graphic_picture graphicRef71549 graphicRef81821 graphicRef65425 graphicRef79666 \" href=\"UTD.htm?29/18/29994\">",
"     picture 2A-D",
"    </a>",
"    ). The rash in this US outbreak was described as maculopapular in nature on initial presentation; the rash subsequently evolved into vesicles, then pustules, which eventually crusted within a two- to three-week period [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16439/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nine of the 34 patients were hospitalized for a variety of reasons, including nausea, vomiting and dysphagia. The discharge diagnoses of two of the most seriously ill patients were encephalopathy and a retropharyngeal abscess. All of the patients in this case series survived with supportive therapy; no antiviral therapy was administered. Multiple nonspecific laboratory findings were also noted including abnormal aminotransferases, leukocytosis, mild thrombocytopenia, and hypoalbuminemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although clinical features are helpful in making the diagnosis, laboratory confirmation of monkeypox virus is necessary to differentiate this disease from those caused by other potential etiologies. Diagnostic assays include virus isolation (in mammalian cell cultures), electron microscopy, real-time PCR, ELISA, and immunofluorescent antibody assay [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16439/abstract/1,20\">",
"     1,20",
"    </a>",
"    ]. Characteristic brick-shaped poxvirus virions are found on electron microscopy. Histopathologic analysis may demonstrate ballooning degeneration of keratinocytes, prominent spongiosis, dermal edema, and acute inflammation; however these findings can also be seen in other viral infections [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16439/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Using sera from patients obtained during the 2003 United States outbreak, the CDC developed an immunoglobulin M-capture and an IgG enzyme-linked immunosorbent assay (ELISA) that demonstrated recent monkeypox virus infection. Serum IgM and IgG antibodies were detected five and eight days after onset of rash, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16439/abstract/22\">",
"     22",
"    </a>",
"    ]. Other experimental antibody and cellular based assays are under development, which may be useful for the prospective and retrospective diagnosis of monkeypox [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16439/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If the diagnosis of monkeypox is being considered, local and state public health officials, along with the CDC, should be notified so that the samples are quickly processed. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two other infections need to be considered in the differential diagnosis of monkeypox: varicella and smallpox.",
"   </p>",
"   <p>",
"    Given the worldwide eradication of smallpox, the most likely diagnostic consideration is varicella (chickenpox). Unlike varicella where vesicular lesions are characteristically in different stages of development and healing when the patient is examined, monkeypox lesions are all generally at the same stage. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/44/33480?source=see_link\">",
"     \"Clinical features of varicella-zoster virus infection: Chickenpox\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because of concerns regarding bioterrorism, it is also important to consider the possibility of smallpox in the differential diagnosis of a patient who has not been in the rain forests of Africa or exposed to animals [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16439/abstract/6\">",
"     6",
"    </a>",
"    ]. Lymphadenopathy, which has been observed in the majority of unvaccinated patients, is a key distinguishing feature of monkeypox [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16439/abstract/10\">",
"     10",
"    </a>",
"    ]. Lymphadenopathy can occur in the submandibular, cervical or inguinal regions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/46/22247?source=see_link\">",
"     \"Identifying and managing casualties of biological terrorism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/61/35797?source=see_link\">",
"     \"The epidemiology, pathogenesis, and clinical manifestations of smallpox\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Also in the differential diagnosis is Tanapox, another African poxvirus that causes a febrile prodrome and skin lesions that resolve over several weeks without sequelae. A case of tanapox infection was diagnosed using electron microscopy and DNA analysis (polymerase chain reaction testing) of a biopsied skin lesion in an American college student who had worked in the Republic of Congo for eight weeks caring for chimpanzees; none of the others working with these animals developed the infection [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16439/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Orf and bovine stomatitis (also caused by parapoxviruses) can produce localized skin lesions similar to those of monkeypox, but can be differentiated by an experienced microscopist by morphologic features on electron microscopy. Parapoxvirions are slightly smaller than orthopoxvirus virions and have a more regular surface pattern than orthopoxviruses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     PATIENT MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5998810\">",
"    <span class=\"h2\">",
"     Supportive care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients have mild disease and recover without medical intervention. Others who have risk factors for dehydration (eg, nausea, vomiting, dysphagia) may require a short hospital stay for intravenous hydration. For the seriously ill patient, supportive care is necessary until the patient recovers from the infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3087553\">",
"    <span class=\"h2\">",
"     Cidofovir",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/2/20517?source=see_link\">",
"     Cidofovir",
"    </a>",
"    has in vitro activity against monkeypox and has been shown to be effective against lethal challenge in animal models [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16439/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]. However, there are no clinical data regarding its efficacy against monkeypox infection in humans and its use is associated with significant adverse events, including nephrotoxicity.",
"   </p>",
"   <p>",
"    Clinical consultation for guidance regarding the management of life-threatening cases of monkeypox is available from the CDC (1-800-232-4636). CDC guidelines for management of monkeypox during an outbreak can be found at",
"    <a class=\"external\" href=\"file://www.cdc.gov/ncidod/monkeypox/clinicians.htm\">",
"     www.cdc.gov/ncidod/monkeypox/clinicians.htm",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/47/37620?source=see_link\">",
"     \"Cidofovir: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3087560\">",
"    <span class=\"h2\">",
"     Drugs in development",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drugs that are under development to treat variola virus will likely be effective against monkeypox as well [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16439/abstract/27\">",
"     27",
"    </a>",
"    ]. The new anti-orthopoxvirus drug ST-246 (Tecovirimat), which is being studied as a therapeutic agent against smallpox, also protects non-human primates from lethal monkeypox virus infections [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16439/abstract/28\">",
"     28",
"    </a>",
"    ] and thus will likely be efficacious in humans against this infection [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16439/abstract/29\">",
"     29",
"    </a>",
"    ]. ST-246 is a specific and potent inhibitor of an orthopoxvirus protein that is critical for formation of an infectious virus particle that is essential for dissemination within an infected host.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3087519\">",
"    <span class=\"h1\">",
"     MORTALITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In central Africa, the fatality rate is approximately 10 percent and deaths generally occur in the second week of illness [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16439/abstract/1,30\">",
"     1,30",
"    </a>",
"    ]. In contrast, there were no deaths in the outbreak in the United States. These more favorable outcomes in the United States may be related to a healthier patient population, greater availability of supportive medical care, and a less virulent strain of monkeypox, which was imported from the West African nation of Ghana [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16439/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data suggest that prior immunization with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/24/18823?source=see_link\">",
"     smallpox vaccine",
"    </a>",
"    prevents infection and ameliorates symptoms. The role of postexposure prophylaxis with smallpox vaccine or vaccinia immunoglobulin is unclear, as discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3087222\">",
"    <span class=\"h2\">",
"     History of prior smallpox immunization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/24/18823?source=see_link\">",
"     smallpox vaccination",
"    </a>",
"    with vaccinia virus has a significant protective effect against acquisition of monkeypox virus and may ameliorate the clinical manifestations of this infection [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16439/abstract/5,18\">",
"     5,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In Africa, secondary attacks rates varied greatly among 2278 household contacts depending on their prior",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/24/18823?source=see_link\">",
"     smallpox vaccination",
"    </a>",
"    status (7.5 compared with 1.3 percent in vaccinated and unvaccinated subjects) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16439/abstract/17\">",
"     17",
"    </a>",
"    ]. In the study that showed an increasing incidence of human monkeypox cases in Africa [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16439/abstract/14\">",
"     14",
"    </a>",
"    ], vaccinated people had a fivefold lower risk of monkeypox as compared with unvaccinated persons (0.78 versus 4.05 per 10,000). In that study, vaccine efficacy was estimated to be approximately 81 percent in those with a distant history of smallpox vaccination.",
"   </p>",
"   <p>",
"    In the US outbreak, further investigation using experimental techniques identified three additional monkeypox exposures in individuals who had previously received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/24/18823?source=see_link\">",
"     smallpox vaccination",
"    </a>",
"    13, 29 and 48 years prior to exposure to monkeypox [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16439/abstract/18\">",
"     18",
"    </a>",
"    ]. These individuals were unaware that they had been infected because they did not have any recognizable disease symptoms. These findings suggested that the US monkeypox outbreak was larger than previously realized. Furthermore, cross-protective antiviral immunity against West African monkeypox can potentially be maintained for decades after smallpox vaccination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3087289\">",
"    <span class=\"h2\">",
"     Postexposure vaccination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since prior vaccination with vaccinia virus protects against monkeypox infection, the CDC recommended vaccination with vaccinia virus for the limited number of individuals exposed to monkeypox in the 2003 United States outbreak, including children and pregnant women. The CDC also recommended pre-exposure vaccination for those involved in the investigation of the outbreak and for healthcare workers caring for patients with monkeypox [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16439/abstract/8,10\">",
"     8,10",
"    </a>",
"    ]. Twenty-eight adults and two children received the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/24/18823?source=see_link\">",
"     smallpox vaccine",
"    </a>",
"    for this purpose and no cases of monkeypox were identified among these recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16439/abstract/10\">",
"     10",
"    </a>",
"    ]. Furthermore, no cases of monkeypox were identified during pregnancy during the 2003 outbreak; it is not known if the infection carries a different prognosis in pregnant women [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16439/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based on historical data on post-exposure vaccination for smallpox with vaccinia vaccine, the optimal time for monkeypox post-exposure vaccination is within four days; however, vaccination can be considered for up to 14 days of exposure, according to the CDC [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16439/abstract/32\">",
"     32",
"    </a>",
"    ]. Close contact is defined as direct exposure within six feet of a probable or confirmed monkeypox case in an animal with respiratory symptoms such as nasal discharge, cough, or conjunctivitis in a setting where the animal has been manipulated (eg, an exam room) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16439/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/7/40057?source=see_link\">",
"     \"Vaccinia virus as the smallpox vaccine\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/53/32602?source=see_link&amp;anchor=H29#H29\">",
"     \"Immunizations during pregnancy\", section on 'Smallpox'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3087407\">",
"    <span class=\"h2\">",
"     Vaccinia immune globulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/33/6677?source=see_link\">",
"     vaccinia immune globulin",
"    </a>",
"    may be considered in immunosuppressed patients with an exposure history, since immunization with vaccinia virus vaccine is contraindicated [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16439/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3087229\">",
"    <span class=\"h2\">",
"     Hospitalized patients with possible monkeypox",
"    </span>",
"    &nbsp;&mdash;&nbsp;Use of both contact and airborne precautions are recommended for any generalized vesicular rash of unknown etiology in which monkeypox and smallpox are included in the differential diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16439/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    During the first week of the rash, persons with suspected monkeypox should be considered infectious and be isolated until all scabs separate and results of throat swab PCR are negative [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16439/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3087596\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Monkeypox is a viral zoonotic infection that results in a rash similar to smallpox. However, the person-to-person spread and the mortality from a monkeypox infection are significantly lower than for smallpox. Clinically, these two viral infections are difficult to distinguish, raising concerns that monkeypox could be used for bioterrorism. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Monkeypox, an orthopoxvirus, was first isolated in the late 1950s from a colony of sick monkeys. The virus is in the same genus as variola (causative agent of smallpox) and vaccinia viruses (the virus used in",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/24/18823?source=see_link\">",
"       smallpox vaccine",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Virology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The virus is acquired through contact with the animal's blood or through a bite. Monkeys and humans are incidental hosts; the reservoir remains unknown but is likely to be rodents. (See",
"      <a class=\"local\" href=\"#H5779046\">",
"       'Transmission'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Epidemiologic surveys and outbreak investigations have found that prior smallpox immunization protects against monkeypox infection and modifies clinical disease. (See",
"      <a class=\"local\" href=\"#H5779060\">",
"       'Eradication of smallpox and impact on monkeypox'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The incubation period from exposure to clinical illness is less than two weeks. (See",
"      <a class=\"local\" href=\"#H3086988\">",
"       'Incubation period'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Predominant symptoms of monkeypox include fever, rash, lymphadenopathy, myalgias, and chills. Most patients with monkeypox have a mild illness; those with nausea, vomiting, or dysphagia may need hospitalization for intravenous hydration. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although clinical features are helpful in making the diagnosis, laboratory confirmation of monkeypox virus is necessary to differentiate this disease from those caused by other potential etiologies. Diagnostic assays include virus isolation (in mammalian cell cultures), electron microscopy, real-time PCR, ELISA, and immunofluorescent antibody assay. If the diagnosis of monkeypox is being considered, local and state public health officials, along with the CDC, should be notified. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Varicella and smallpox should be included in the differential diagnosis of monkeypox. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/2/20517?source=see_link\">",
"       Cidofovir",
"      </a>",
"      and a new anti-orthopoxvirus drug (ST-246) have in vitro activity against monkeypox and have been shown to be effective against lethal challenge in animal models. However, there are no clinical data regarding the efficacy of these against monkeypox infection in humans. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Patient management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Both contact and airborne precautions should be initiated in any hospitalized patients with generalized vesicular rash of unknown etiology in which monkeypox and smallpox are included in the differential diagnosis. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16439/abstract/1\">",
"      Nalca A, Rimoin AW, Bavari S, Whitehouse CA. Reemergence of monkeypox: prevalence, diagnostics, and countermeasures. Clin Infect Dis 2005; 41:1765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16439/abstract/2\">",
"      Chen N, Li G, Liszewski MK, et al. Virulence differences between monkeypox virus isolates from West Africa and the Congo basin. Virology 2005; 340:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16439/abstract/3\">",
"      Likos AM, Sammons SA, Olson VA, et al. A tale of two clades: monkeypox viruses. J Gen Virol 2005; 86:2661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16439/abstract/4\">",
"      Centers for Disease Control and Prevention (CDC). Human monkeypox -- Kasai Oriental, Democratic Republic of Congo, February 1996-October 1997. MMWR Morb Mortal Wkly Rep 1997; 46:1168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16439/abstract/5\">",
"      Heymann DL, Szczeniowski M, Esteves K. Re-emergence of monkeypox in Africa: a review of the past six years. Br Med Bull 1998; 54:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16439/abstract/6\">",
"      Breman JG, Henderson DA. Poxvirus dilemmas--monkeypox, smallpox, and biologic terrorism. N Engl J Med 1998; 339:556.",
"     </a>",
"    </li>",
"    <li>",
"     WHO. Technical Advisory Group on Human Monkeypox. Report of a WHO meeting. Geneva, Switzerland, 11-12 January 1999.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16439/abstract/8\">",
"      Centers for Disease Control and Prevention (CDC). Update: multistate outbreak of monkeypox--Illinois, Indiana, Kansas, Missouri, Ohio, and Wisconsin, 2003. MMWR Morb Mortal Wkly Rep 2003; 52:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16439/abstract/9\">",
"      Reed KD, Melski JW, Graham MB, et al. The detection of monkeypox in humans in the Western Hemisphere. N Engl J Med 2004; 350:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16439/abstract/10\">",
"      Centers for Disease Control and Prevention (CDC). Multistate outbreak of monkeypox--Illinois, Indiana, and Wisconsin, 2003. MMWR Morb Mortal Wkly Rep 2003; 52:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16439/abstract/11\">",
"      Hutin YJ, Williams RJ, Malfait P, et al. Outbreak of human monkeypox, Democratic Republic of Congo, 1996 to 1997. Emerg Infect Dis 2001; 7:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16439/abstract/12\">",
"      Reynolds MG, Yorita KL, Kuehnert MJ, et al. Clinical manifestations of human monkeypox influenced by route of infection. J Infect Dis 2006; 194:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16439/abstract/13\">",
"      Mukinda VB, Mwema G, Kilundu M, et al. Re-emergence of human monkeypox in Zaire in 1996. Monkeypox Epidemiologic Working Group. Lancet 1997; 349:1449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16439/abstract/14\">",
"      Rimoin AW, Mulembakani PM, Johnston SC, et al. Major increase in human monkeypox incidence 30 years after smallpox vaccination campaigns cease in the Democratic Republic of Congo. Proc Natl Acad Sci U S A 2010; 107:16262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16439/abstract/15\">",
"      Reynolds MG, Davidson WB, Curns AT, et al. Spectrum of infection and risk factors for human monkeypox, United States, 2003. Emerg Infect Dis 2007; 13:1332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16439/abstract/16\">",
"      Croft DR, Sotir MJ, Williams CJ, et al. Occupational risks during a monkeypox outbreak, Wisconsin, 2003. Emerg Infect Dis 2007; 13:1150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16439/abstract/17\">",
"      Fleischauer AT, Kile JC, Davidson M, et al. Evaluation of human-to-human transmission of monkeypox from infected patients to health care workers. Clin Infect Dis 2005; 40:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16439/abstract/18\">",
"      Hammarlund E, Lewis MW, Carter SV, et al. Multiple diagnostic techniques identify previously vaccinated individuals with protective immunity against monkeypox. Nat Med 2005; 11:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16439/abstract/19\">",
"      Huhn GD, Bauer AM, Yorita K, et al. Clinical characteristics of human monkeypox, and risk factors for severe disease. Clin Infect Dis 2005; 41:1742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16439/abstract/20\">",
"      Olson VA, Laue T, Laker MT, et al. Real-time PCR system for detection of orthopoxviruses and simultaneous identification of smallpox virus. J Clin Microbiol 2004; 42:1940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16439/abstract/21\">",
"      Bayer-Garner IB. Monkeypox virus: histologic, immunohistochemical and electron-microscopic findings. J Cutan Pathol 2005; 32:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16439/abstract/22\">",
"      Karem KL, Reynolds M, Braden Z, et al. characterization of acute-phase humoral immunity to monkeypox: use of immunoglobulin M enzyme-linked immunosorbent assay for detection of monkeypox infection during the 2003 North American outbreak. Clin Diagn Lab Immunol 2005; 12:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16439/abstract/23\">",
"      Dhar AD, Werchniak AE, Li Y, et al. Tanapox infection in a college student. N Engl J Med 2004; 350:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16439/abstract/24\">",
"      Baker RO, Bray M, Huggins JW. Potential antiviral therapeutics for smallpox, monkeypox and other orthopoxvirus infections. Antiviral Res 2003; 57:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16439/abstract/25\">",
"      Smee DF. Progress in the discovery of compounds inhibiting orthopoxviruses in animal models. Antivir Chem Chemother 2008; 19:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16439/abstract/26\">",
"      Stittelaar KJ, Neyts J, Naesens L, et al. Antiviral treatment is more effective than smallpox vaccination upon lethal monkeypox virus infection. Nature 2006; 439:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16439/abstract/27\">",
"      Sbrana E, Jordan R, Hruby DE, et al. Efficacy of the antipoxvirus compound ST-246 for treatment of severe orthopoxvirus infection. Am J Trop Med Hyg 2007; 76:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16439/abstract/28\">",
"      Huggins J, Goff A, Hensley L, et al. Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246. Antimicrob Agents Chemother 2009; 53:2620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16439/abstract/29\">",
"      Yang G, Pevear DC, Davies MH, et al. An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus Challenge. J Virol 2005; 79:13139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16439/abstract/30\">",
"      Frey SE, Belshe RB. Poxvirus zoonoses--putting pocks into context. N Engl J Med 2004; 350:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16439/abstract/31\">",
"      Jamieson DJ, Cono J, Richards CL, Treadwell TA. The role of the obstetrician-gynecologist in emerging infectious diseases: monkeypox and pregnancy. Obstet Gynecol 2004; 103:754.",
"     </a>",
"    </li>",
"    <li>",
"     Updated interim CDC guidance for use of smallpox vaccine, cidofovir, and vaccinia immune globulin (VIG) for prevention and treatment in the setting of an outbreak of monkeypox infections. www.cdc.gov/ncidod/monkeypox/treatmentguidelines.htm (Accessed on September 05, 2008).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8295 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-EE7AE732F8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_3_16439=[""].join("\n");
var outline_f16_3_16439=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H3087596\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      VIROLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5779046\">",
"      Transmission",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5779060\">",
"      Eradication of smallpox and impact on monkeypox",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Africa",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - United States",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3086988\">",
"      INCUBATION PERIOD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3087483\">",
"      Outbreaks in Africa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3087007\">",
"      United States outbreak",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      PATIENT MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5998810\">",
"      Supportive care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3087553\">",
"      Cidofovir",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3087560\">",
"      Drugs in development",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3087519\">",
"      MORTALITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3087222\">",
"      History of prior smallpox immunization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3087289\">",
"      Postexposure vaccination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3087407\">",
"      Vaccinia immune globulin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3087229\">",
"      Hospitalized patients with possible monkeypox",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3087596\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/8295\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/8295|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/23/13683\" title=\"picture 1\">",
"      Vaccinia virion on EM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/63/21492\" title=\"picture 2A\">",
"      Primary site lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/31/17907\" title=\"picture 2B\">",
"      Secondary lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/63/40959\" title=\"picture 2C\">",
"      Disseminated acral lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/36/37441\" title=\"picture 2D\">",
"      Monkeypox lesions",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/47/37620?source=related_link\">",
"      Cidofovir: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/44/33480?source=related_link\">",
"      Clinical features of varicella-zoster virus infection: Chickenpox",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/46/22247?source=related_link\">",
"      Identifying and managing casualties of biological terrorism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/53/32602?source=related_link\">",
"      Immunizations during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/61/35797?source=related_link\">",
"      The epidemiology, pathogenesis, and clinical manifestations of smallpox",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/7/40057?source=related_link\">",
"      Vaccinia virus as the smallpox vaccine",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_3_16440="Craniopharyngioma MRI I";
var content_f16_3_16440=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F72783%7EONC%2F80882&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F72783%7EONC%2F80882&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Craniopharyngioma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 286px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Magnetic resonance imaging in a patient with craniopharyngioma reveals hyperintense mass relative to gray matter (arrow) with the epicenter in the sella turcica and extending superiorly to displace hypothalmic stalk.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Lawrence Recht, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Craniopharyngioma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 435px; height: 268px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Unenhanced and enhanced magnetic resonance imaging of the brain in a 55 year-old patient with decreased vision on the right due to a craniopharygioma. There is a midline, 2.2 cm, enhancing suprasellar mass bordered anteriorly by the optic chiasm, superiorly by the third ventricle, and posteriorly by the interpenduncular cistern. There is no calcification.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Lawrence Recht, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_3_16440=[""].join("\n");
var outline_f16_3_16440=null;
var title_f16_3_16441="Needle cricothyroidotomy with percutaneous transtracheal ventilation";
var content_f16_3_16441=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Needle cricothyroidotomy with percutaneous transtracheal ventilation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/3/16441/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/3/16441/contributors\">",
"     Manoj K Mittal, MD, MRCP (UK), FAAP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/3/16441/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/3/16441/contributors\">",
"     Anne M Stack, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/3/16441/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/3/16441/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/3/16441/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 22, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Needle cricothyroidotomy involves passing an over-the-needle catheter through the cricothyroid membrane (",
"    <a class=\"graphic graphic_figure graphicRef73518 \" href=\"UTD.htm?14/22/14696\">",
"     figure 1",
"    </a>",
"    ). This procedure provides a temporary secure airway to oxygenate and ventilate a patient in severe respiratory distress in whom less invasive techniques (eg, bag-valve-mask ventilation, laryngeal mask ventilation, endotracheal intubation) have failed or are not likely to be successful (ie, \"can't intubate, can't ventilate\") [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16441/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. The delivery of oxygen to the lungs through an over-the-needle catheter inserted through the skin into the trachea using a high pressure gas source is considered a form of conventional ventilation called percutaneous transtracheal ventilation (PTV).",
"   </p>",
"   <p>",
"    Although sometimes a point of confusion, PTV should not be mistaken for transtracheal jet ventilation, which is not considered conventional ventilation and refers to high frequency, low tidal volume ventilation and needs specialized ventilators usually only available in the operating room or intensive care unit. Although a technically different treatment, the term \"jet ventilation\" has also been used to describe conventional ventilation using a high pressure oxygen source via a percutaneous catheter [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16441/abstract/5-7\">",
"     5-7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Needle cricothyroidotomy differs from surgical cricothyroidotomy in that surgical cricothyroidotomy involves making an incision in the cricothyroid membrane and passing a tracheostomy or endotracheal tube through it into the trachea [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16441/abstract/4\">",
"     4",
"    </a>",
"    ]. Needle cricothyroidotomy may be performed on patients of any age but is considered to be preferable to surgical cricothyroidotomy in infants and children up to 10 to 12 years of age because it is anatomically easier to perform with less potential damage to the larynx and surrounding structures [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16441/abstract/8-11\">",
"     8-11",
"    </a>",
"    ]. However, surgical cricothyroidotomy provides more effective ventilation than needle cricothyroidotomy because of the larger diameter tube used and is typically chosen instead of needle cricothyroidotomy in adults and children over 10 to 12 years of age.",
"   </p>",
"   <p>",
"    Needle cricothyroidotomy and percutaneous transtracheal ventilation will be discussed here. Surgical cricothyroidotomy is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/50/4905?source=see_link\">",
"     \"Emergent surgical cricothyrotomy (cricothyroidotomy)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is important to distinguish between the different methods of emergency airway access and specialized ventilation. For the purposes of this review, definitions are as follows:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Needle cricothyroidotomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Needle cricothyroidotomy involves passing an over-the-needle catheter through the cricothyroid membrane (",
"    <a class=\"graphic graphic_figure graphicRef73518 \" href=\"UTD.htm?14/22/14696\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Surgical cricothyroidotomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical cricothyroidotomy is an emergent airway approach in which the clinician makes an incision in the cricothyroid membrane and passes a tracheostomy or endotracheal tube into the trachea. The standard, four step, and Seldinger techniques are common methods of surgical cricothyroidotomy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/50/4905?source=see_link\">",
"     \"Emergent surgical cricothyrotomy (cricothyroidotomy)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Percutaneous transtracheal ventilation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Percutaneous transtracheal ventilation (PTV) involves oxygenation and ventilation via a needle or surgical cricothyroidotomy using an improvised ventilation device. Confusingly, although this is a form of conventional ventilation, it is sometimes referring to as \"jet ventilation\" when a high pressure source is used to deliver oxygen. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Bag-valve-mask connector options'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H22\">",
"     'Oxygen tubing connector options'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Transtracheal jet ventilation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transtracheal jet ventilation refers to high frequency, low tidal volume ventilation provided via a laryngeal catheter by specialized ventilators that are usually only available in the operating room or intensive care unit [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16441/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. This procedure is occasionally employed in the operating room when a difficult airway is anticipated (eg, Treacher Collins syndrome, Robin sequence, head and neck surgery with supraglottic or glottic obstruction) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16441/abstract/12-15\">",
"     12-15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary indication is inability to maintain the airway with noninvasive standard airway procedures (eg, bag-valve-mask ventilation, endotracheal intubation) or rescue procedures (eg, laryngeal mask airway). The typical setting involves patients with pathologic processes that cause distortion of the upper airway anatomy, for example [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16441/abstract/3,16-18\">",
"     3,16-18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Airway obstruction by uncontrolled bleeding into the oral cavity",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      vomiting",
"     </li>",
"     <li>",
"      Severe maxillofacial trauma - blunt, penetrating, or associated with mandibular fracture",
"     </li>",
"     <li>",
"      Laryngeal foreign body that cannot be removed expeditiously",
"     </li>",
"     <li>",
"      Swelling of upper airway structures",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Infection, like epiglottitis or Ludwig's angina",
"     </li>",
"     <li>",
"      Allergic or immunologic reaction, as from food allergy or hereditary angioedema",
"     </li>",
"     <li>",
"      Chemical or thermal burns to the epiglottis and upper airway",
"     </li>",
"     <li>",
"      Post-extubation glottic edema",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CONTRAINDICATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Absolute",
"    </span>",
"    &nbsp;&mdash;&nbsp;Needle cricothyroidotomy with percutaneous transtracheal ventilation (PTV) is absolutely contraindicated when the airway is maintainable through noninvasive means.",
"   </p>",
"   <p>",
"    In addition, needle cricothyroidotomy with PTV should",
"    <strong>",
"     not",
"    </strong>",
"    be performed when damage to the larynx, cricoid cartilage, or trachea preclude successful oxygenation and ventilation via a transtracheal catheter, for example:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Laryngeal injury with known damage to cricoid cartilage (laryngeal fracture)",
"     </li>",
"     <li>",
"      Tracheal rupture",
"     </li>",
"     <li>",
"      Tracheal transection with distal tracheal retraction into the mediastinum",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Relative",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several relative contraindications arise in situations where anatomic distortion increases the risk of airway complications or where excessive bleeding may be encountered during needle cricothyroidotomy and PTV as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Anterior neck swelling (eg, angioedema, hematoma) that obscures anatomical landmarks",
"     </li>",
"     <li>",
"      Anatomic anomalies or distortion of the larynx and trachea (eg, repaired tracheal anomalies, Hurler syndrome) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/6/7274?source=see_link&amp;anchor=H5#H5\">",
"       \"Clinical features and diagnosis of the mucopolysaccharidoses\", section on 'Hurler syndrome'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Bleeding disorder",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, in most instances, the benefit of securing an airway will outweigh the risk of performing needle cricothyroidotomy in these circumstances.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     PRECAUTIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Complete upper airway obstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;In routine use of percutaneous transtracheal ventilation (PTV) through a catheter, much of the expired air comes out of the mouth and nose. Thus, with complete upper airway obstruction, egress of expired air is difficult. Initial studies in animals suggested that PTV in the setting of complete upper airway obstruction led to development of massive distension of lungs, severe barotrauma, and death [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16441/abstract/19\">",
"     19",
"    </a>",
"    ]. Subsequent studies have shown successful use of PTV in settings of complete upper airway obstruction using modified techniques that consist of prolonged expiratory time, larger internal diameter catheters, and lower oxygen flow rates [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16441/abstract/20-22\">",
"     20-22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    PTV may be used successfully in partial laryngeal obstruction as the \"ball-valve\" effect, while constraining natural inspiration, adequately permits exhalation [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16441/abstract/14,23-25\">",
"     14,23-25",
"    </a>",
"    ]. For infants and young children with complete upper airway obstruction and where other methods have been unsuccessful, it is reasonable to use PTV. Ventilatory methods should use a longer expiratory time (eg, I:E ratio of 1:8 to 1:10), lower oxygen delivery pressure and flow rate, and as large a catheter as possible. In addition, the clinician should carefully monitor for chest rise and fall with inspiration and expiration. Diminished chest fall with expiration should lead to further reduction in respiratory rate, longer expiratory time, and emergent chest radiography to look for signs of pulmonary barotrauma. (See",
"    <a class=\"local\" href=\"#H34\">",
"     'Performing transtracheal ventilation'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cricothyroid membrane, as the name implies, is bound by the cricoid cartilage inferiorly and the thyroid cartilage superiorly (",
"    <a class=\"graphic graphic_figure graphicRef73518 \" href=\"UTD.htm?14/22/14696\">",
"     figure 1",
"    </a>",
"    ). The key anatomic landmarks are (from cephalad to caudad): hyoid cartilage, thyroid cartilage, cricothyroid membrane, cricoid cartilage, and the tracheal rings.",
"   </p>",
"   <p>",
"    In older children and adolescents, the laryngeal prominence at the upper border of the thyroid cartilage is easily felt. The thyroid cartilage can then be followed inferiorly to locate the cricothyroid membrane.",
"   </p>",
"   <p>",
"    In infants and younger children, the laryngeal prominence is not developed, making it difficult to identify the thyroid cartilage. Instead, it is easier to follow the tracheal rings superiorly to locate the prominence of the cricoid cartilage. The cricothyroid membrane is located just superior to the cricoid cartilage. If the cricothyroid membrane cannot be located with certainty in an infant or a young child, percutaneous transtracheal ventilation can be safely performed by introducing the needle between the tracheal cartilages [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16441/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The cricothyroid arteries and veins usually overlie the apical portion of the membrane and come from the sides, anastomosing in the midline [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16441/abstract/26\">",
"     26",
"    </a>",
"    ]. Thus, needle cricothyroidotomy should be attempted in the central, lower portion of the membrane (",
"    <a class=\"graphic graphic_figure graphicRef73518 \" href=\"UTD.htm?14/22/14696\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In fresh adult cadavers, the size of the cricothyroid membrane was found to vary from 8 to 19 mm (mean 13.7 mm) in the vertical dimension, and from 9 to 19 mm (mean 12.4 mm) in the transverse dimension [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16441/abstract/27\">",
"     27",
"    </a>",
"    ]. These data suggest that catheters up to 13-gauge can be safely used in a patient with a fully developed airway. The cricothyroid membrane has a mean height of 2.6 mm (SD: 0.7) and width of 3 mm (SD: 0.6) in neonatal cadavers (mean height of 44.9 cm and a mean weight of 2 kg) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16441/abstract/28\">",
"     28",
"    </a>",
"    ]. The clinician should place the largest catheter possible using this limited information and palpation of the cricothyroid membrane as a guide. The mean depth of tissue overlying cricothyroid membrane in adults is about 2.3 mm [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16441/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     PHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Needle cricothyroidotomy was originally used for passive transtracheal oxygenation in the 1950s [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16441/abstract/30\">",
"     30",
"    </a>",
"    ]. Eventually, needle cricothyroidotomy with percutaneous transtracheal ventilation (PTV) emerged as the invasive rescue method of choice because it provided oxygenation as well as clearance of carbon dioxide. This approach could sustain life for a longer period of time than passive transtracheal oxygenation alone [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16441/abstract/1,12,31-33\">",
"     1,12,31-33",
"    </a>",
"    ]. Smith and Ravussin were among the first to document successful use of needle cricothyroidotomy with PTV in infants and children in the 1970s [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16441/abstract/12,34\">",
"     12,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Delivered tidal volume during PTV is affected by multiple factors, including inspiratory pressure, duration of inspiration, airway resistance, size of catheter, and lung compliance [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16441/abstract/33,35\">",
"     33,35",
"    </a>",
"    ]. PTV is less efficient than ventilation through endotracheal intubation because up to one-third of oxygen flow delivered to the catheter tip passes up through the glottic opening and out the nose and mouth [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16441/abstract/32,35\">",
"     32,35",
"    </a>",
"    ]. High pressure oxygen delivery systems are optimal to provide effective ventilation through the relatively narrow catheters used for PTV. However, low pressure systems (eg, self-inflating bag connected to the cricothyroidotomy catheter via a 3.0 mm internal diameter endotracheal tube adapter, 7.0 mm ID ETT adapter connected through a 3 cc syringe, (",
"    <a class=\"graphic graphic_figure graphicRef52559 \" href=\"UTD.htm?27/49/28447\">",
"     figure 2",
"    </a>",
"    )) are sufficient in most patients if a high flow oxygen system is not available [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16441/abstract/2,6,36,37\">",
"     2,6,36,37",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Equipment'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In adults, PTV is typically accomplished using a 50 pounds per square inch (psi) (350 kPa) oxygen source and a 13- to 16-gauge over-the-needle catheter [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16441/abstract/3,25,32\">",
"     3,25,32",
"    </a>",
"    ]. Marr and Yamamoto showed that catheter size (13- to 16-gauge) does not appear to substantially affect gas flow rates when using wall outlet oxygen because gas flows in a turbulent fashion under high pressure through these narrow catheters [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16441/abstract/36\">",
"     36",
"    </a>",
"    ]. Large cannula (&gt;4 mm), inserted via the Seldinger technique, enable ventilation with lower pressures in adults but require either a cuff or upper airway obstruction to prevent gas from escaping through the upper airway [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16441/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Lower driving pressures (25 to 35 psi [172 to 241 kPa]) are used in infants and younger children (under 12 years of age) in order to prevent barotrauma [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16441/abstract/12\">",
"     12",
"    </a>",
"    ]. Smaller catheters (16- to 18-gauge) are typically placed due to the anatomic limitation posed by the cricothyroid membrane in the pediatric population. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Anatomy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Once ventilation is established, exhalation through the transtracheal catheter is insufficient to prevent hyperinflation of the lungs. However, in most instances where PTV is used, the patient's airway remains sufficiently patent to permit exhalation through the nose and mouth [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16441/abstract/3,24\">",
"     3,24",
"    </a>",
"    ]. In situations where complete airway obstruction exists, the clinician should use longer expiratory time and lower oxygen delivery pressure. In addition, chest rise and fall with inspiration and expiration should be carefully monitored. Diminished chest fall with expiration should lead to further reduction in respiratory rate, prolongation of expiratory time, and emergent chest radiography to look for signs for pulmonary barotrauma. (See",
"    <a class=\"local\" href=\"#H34\">",
"     'Performing transtracheal ventilation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    PTV provides less efficient ventilation than endotracheal intubation. Because of the concern for carbon dioxide retention with PTV, the traditional approach has been to use it as a short term (eg, less than 45 minutes) temporizing airway measure [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16441/abstract/7\">",
"     7",
"    </a>",
"    ]. However, when oxygenation is well maintained, even relatively high levels of hypercarbia may be well tolerated, thus permitting its use for many hours at a time [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16441/abstract/2,7,38\">",
"     2,7,38",
"    </a>",
"    ]. Regardless, the clinician should still rapidly seek to definitively secure the airway in most patients who require PTV, especially in settings complicated by increased intracranial pressure (because hypercarbia worsens intracranial pressure) or complete upper airway obstruction (increased risk of barotrauma).",
"   </p>",
"   <p>",
"    There is no risk of gastric dilatation with needle cricothyroidotomy and PTV. The flow of gas up the airway aids in the expulsion of secretions, minimizing the need for suction and preventing pulmonary aspiration [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16441/abstract/32,39\">",
"     32,39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Using a canine model, researchers showed that it is not necessary to induce paralysis when using PTV for emergency ventilation of a sedated patient [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16441/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     PREPARATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Needle cricothyroidotomy with percutaneous transtracheal ventilation (PTV) is an invasive emergent airway procedure that is life saving, albeit with significant potential morbidity. Thus, proper patient selection is essential. The key indication consists of inability to maintain a patient's airway utilizing noninvasive means (eg, bag-valve-mask ventilation, endotracheal intubation, laryngeal mask airway). These patients cannot be intubated and cannot be ventilated. Proposed criteria include [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16441/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inability to maintain adequate oxygenation with bag-valve-mask ventilation using 100 percent oxygen",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    AND",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inability to place or utilize a laryngeal mask airway",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    AND",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inability to endotracheally intubate (eg, three or more failed attempts or failure to intubate after 10 minutes in a patient who cannot be maintained with bag-valve-mask ventilation or other noninvasive device)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Pathologic processes that cause distortion of the upper airway anatomy comprise the typical scenarios. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Indications'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The presence of subcutaneous emphysema in the neck may indicate tracheal or cricoid injury and is typically a contraindication to the use of this procedure as is transection of the trachea with retraction of the distal end into the mediastinum. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Contraindications'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Special precautions are needed for infants and young children with complete upper airway obstruction, as in the case of a tight foreign body obstructing the larynx. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Complete upper airway obstruction'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Patient counseling/informed consent",
"    </span>",
"    &nbsp;&mdash;&nbsp;Needle cricothyroidotomy with percutaneous transtracheal ventilation is usually an emergent procedure that does not allow for patient",
"    <span class=\"nowrap\">",
"     counseling/informed",
"    </span>",
"    consent prior to the procedure. However, the procedure's necessity, benefits, and risks should be explained to the patient",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    caretaker at the earliest possible time after completion. If feasible, it is ideal for a member of the team not directly involved with the resuscitation to explain the procedure to the family as it is being done.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Equipment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Needle cricothyroidotomy and percutaneous transtracheal ventilation can be performed using standard materials readily available in any hospital. Commercial setups are also attainable [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16441/abstract/3,7,41,42\">",
"     3,7,41,42",
"    </a>",
"    ]. To ensure maximum effectiveness in a highly stressful emergent setting, the author recommends that equipment for PTV, including all the necessary components, be organized and readily available [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16441/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     General equipment",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Universal precautions (gown, cap, mask, eye protection, sterile gloves)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/0/32768?source=see_link\">",
"       Povidone iodine",
"      </a>",
"      for site cleansing",
"     </li>",
"     <li>",
"      Sterile drape",
"     </li>",
"     <li>",
"      1 percent",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/57/37776?source=see_link\">",
"       lidocaine",
"      </a>",
"      without epinephrine in syringe for injection of local anesthesia in the conscious or semi-conscious patient (see",
"      <a class=\"local\" href=\"#H29\">",
"       'Analgesia and sedation'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Three to 10 mL syringe filled with sterile saline",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Catheter (large bore)",
"    </span>",
"    &nbsp;&mdash;&nbsp;AVOID needleless safety catheters that cannot be connected to a syringe (eg, BD InSyte&trade; Autogard&trade;) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16441/abstract/12,44\">",
"     12,44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Infants and young children - 16- to 18-gauge IV catheters",
"     </li>",
"     <li>",
"      Adults and adolescents - 12- (ID 2.8 mm) to 16-gauge (ID 1.5 mm) IV catheters (angiocath) or 6 French transtracheal catheter (2 mm ID, Cook Critical Care) [",
"      <a class=\"abstract\" href=\"UTD.htm?16/3/16441/abstract/3\">",
"       3",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Alternative catheters include vessel dilators from central line kits (7 to 9 French for adults and 5 to 7 French for younger children), a catheter introducer (Arrow Emergency Infusion Device), or a commercially available cricothyroidotomy catheter (eg, Acutronic&trade;) [",
"      <a class=\"abstract\" href=\"UTD.htm?16/3/16441/abstract/15,22,45\">",
"       15,22,45",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Bag-valve-mask connector options",
"    </span>",
"    &nbsp;&mdash;&nbsp;If a bag-valve-mask will be used for patient ventilation, then it should connect to the catheter using one of the following improvised adapters:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Three mL Luer lock syringe with plunger removed with 7.5 mm ID endotracheal tube connector (bag-valve-mask connector) (",
"      <a class=\"graphic graphic_figure graphicRef52559 \" href=\"UTD.htm?27/49/28447\">",
"       figure 2",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      3.0 mm ID endotracheal tube connector attached directly to the catheter (",
"      <a class=\"graphic graphic_figure graphicRef52559 \" href=\"UTD.htm?27/49/28447\">",
"       figure 2",
"      </a>",
"      ) (bag-valve-mask connector)",
"     </li>",
"     <li>",
"      2.5 mm ID endotracheal tube connector attached to cut off IV tubing with Luer lock end connected directly to the catheter (",
"      <a class=\"graphic graphic_figure graphicRef73064 \" href=\"UTD.htm?22/23/22899\">",
"       figure 3",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Oxygen tubing connector options",
"    </span>",
"    &nbsp;&mdash;&nbsp;If oxygen tubing will be used to connect to the oxygen source, then the clinician may use one of the following options:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Direct connection of oxygen tubing to catheter (",
"      <a class=\"graphic graphic_figure graphicRef76530 \" href=\"UTD.htm?9/12/9410\">",
"       figure 4",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Y connector (oxygen tubing) (",
"      <a class=\"graphic graphic_figure graphicRef76530 \" href=\"UTD.htm?9/12/9410\">",
"       figure 4",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Three-way stopcock (oxygen tubing) (",
"      <a class=\"graphic graphic_figure graphicRef50969 \" href=\"UTD.htm?2/14/2273\">",
"       figure 5",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     High pressure oxygen source",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the following oxygen sources is recommended:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hospital wall outlet without a regulator or set at the maximum flow rate of 15",
"      <span class=\"nowrap\">",
"       L/min",
"      </span>",
"      which provides oxygen at 58 psi (400 kPa, 4 atmospheres) for adolescents and adults; for younger children use a maximum flow rate of 10 to 12",
"      <span class=\"nowrap\">",
"       L/min",
"      </span>",
"      which provides oxygen at 25 to 35 psi (172 to 241 kPa, 1.7 to 2.4 atmospheres) [",
"      <a class=\"abstract\" href=\"UTD.htm?16/3/16441/abstract/3,6\">",
"       3,6",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Oxygen tank without interposing a flow valve with flow rates as per a hospital wall outlet [",
"      <a class=\"abstract\" href=\"UTD.htm?16/3/16441/abstract/6\">",
"       6",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Flush valve of a mechanical ventilator",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    DO NOT USE the common gas outlet of the anesthesia machine, as most machines have a pressure limiting valve on the back bar which opens at 5 psi (35 kPa) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16441/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Oxygen tubing or equivalent",
"    </span>",
"    &nbsp;&mdash;&nbsp;The tubing must be capable of withstanding high pressure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Manual in-line valve",
"    </span>",
"    &nbsp;&mdash;&nbsp;The setup must control intermittent flow of oxygen and ventilate the patient, examples include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A permanent, commercially available system (",
"      <a class=\"graphic graphic_figure graphicRef55816 \" href=\"UTD.htm?22/34/23078\">",
"       figure 6",
"      </a>",
"      ) (eg, by Instrumentation Industries, Inc.)",
"     </li>",
"     <li>",
"      A temporary system using Y-connector, side port cut into oxygen tubing, three-way stopcock, or catheter adapter with bag-valve-mask (",
"      <a class=\"graphic graphic_figure graphicRef76530 \" href=\"UTD.htm?9/12/9410\">",
"       figure 4",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef50969 \" href=\"UTD.htm?2/14/2273\">",
"       figure 5",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef52559 \" href=\"UTD.htm?27/49/28447\">",
"       figure 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef73064 \" href=\"UTD.htm?22/23/22899\">",
"       figure 3",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?16/3/16441/abstract/33,36,37,47\">",
"       33,36,37,47",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     PROCEDURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Percutaneous transtracheal ventilation is summarized in the table (",
"    <a class=\"graphic graphic_table graphicRef63745 \" href=\"UTD.htm?7/33/7709\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef70963 \" href=\"UTD.htm?16/56/17288\">",
"     figure 7",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     General considerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Place the patient in the supine position on the stretcher. Unless there is a cervical spine injury (known or suspected), extend the patient's neck to help identify the procedural landmarks and to obtain the widest exposure of the cricothyroid membrane. While assembling the equipment for the procedure, ask an assistant (preferably the respiratory therapist) to preoxygenate the patient by administering high-flow oxygen via face mask if the patient is breathing spontaneously or via bag-valve-mask if not.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Site verification",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinician should locate the cricothyroid membrane by palpating the prominence of the thyroid cartilage in older children, adolescents, and adults and moving the finger inferiorly into the depression between the thyroid and cricoid cartilages.",
"   </p>",
"   <p>",
"    In infants and young children, the clinician should palpate the trachea just above the suprasternal notch and move superiorly until the prominence of the cricoid cartilage is felt. The needle should be placed just above the cricoid cartilage in the midline. If the cricothyroid membrane cannot be located with certainty in an infant or a young child, percutaneous transtracheal ventilation (PTV) can be safely performed by introducing the needle between the tracheal cartilages [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16441/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Anatomy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Although not studied in children, investigators have demonstrated the ability to accurately and rapidly identify the cricothyroid membrane in adult cadavers and live patients using bedside ultrasonography [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16441/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Analgesia and sedation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Under emergent circumstances there may not be time to administer sedative or analgesic medications. The most important goal is to secure the airway. In the case of respiratory depression or arrest, sedation may make matters worse and is not advised. However, if the patient is agitated and struggling and this behavior is impeding the progress of the procedure, a sedative and analgesic can be given to help control the patient.",
"   </p>",
"   <p>",
"    Paralysis or subsequent continuation of paralysis may be considered based on the patient's response to the procedure and adequacy of ventilation achieved. In canine studies, PTV without paralysis has been achieved in sedated animals with unobstructed airways [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16441/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Skin preparation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prepare the skin of the anterior neck with an antiseptic solution (eg, povidone-iodine). If time permits, anesthetize the skin, subcutaneous tissues, and the cricothyroid membrane with a local anesthetic such as 1 percent",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/57/37776?source=see_link\">",
"     lidocaine",
"    </a>",
"    administered through a 27- or 30-gauge needle.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Monitor heart rate and rhythm, blood pressure, respiratory rate, and oxygen saturation throughout the procedure. Lower the patient's gown and sheet to observe the rise and fall of the chest with respiration. Capnography should be used as feasible both during the procedure (to ensure intratracheal location of the needle or the catheter) and during patient ventilation [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16441/abstract/25,48\">",
"     25,48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Once the catheter is in place and percutaneous transtracheal ventilation is established, the site of needle cricothyroidotomy should be observed closely for any kinking or dislodgement of the catheter, subcutaneous emphysema (may indicate dislodgment of the cannula), or bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16441/abstract/3\">",
"     3",
"    </a>",
"    ]. Chest radiographs should be obtained to ensure that the lungs are not over-expanded. Adequacy of PTV should be assessed using clinical parameters as well as frequent blood gas analysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Method",
"    </span>",
"    &nbsp;&mdash;&nbsp;(",
"    <a class=\"graphic graphic_figure graphicRef70963 \" href=\"UTD.htm?16/56/17288\">",
"     figure 7",
"    </a>",
"    )",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h3\">",
"     Needle cricothyroidotomy",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Needle cricothyroidotomy should be performed with universal precautions and sterile technique. The puncture site is cleansed with povidone-iodine solution after sterile gloves have been donned.",
"     </li>",
"     <li>",
"      Hold the trachea in place and provide skin tension with the thumb and middle finger of the non-dominant hand placed on either side of the trachea. Use the index finger to palpate the cricothyroid membrane.",
"     </li>",
"     <li>",
"      Hold a 3 to 10 mL syringe half-filled with saline attached to the needle or the over-the-needle IV catheter in the dominant hand.",
"     </li>",
"     <li>",
"      Place the needle in the midline of the neck at the inferior margin of the cricothyroid membrane (to avoid the cricothyroid blood vessels located superiorly and laterally). Direct it caudally (toward the feet) at an angle of 30 to 45 degrees.",
"     </li>",
"     <li>",
"      Puncture the skin and subcutaneous tissue. Advance the needle while continuously applying negative pressure on the syringe, until air bubbles are seen, confirming intratracheal placement.",
"     </li>",
"     <li>",
"      Advance the catheter forward off the needle until its hub rests at the skin surface. Remove the syringe and the needle.",
"     </li>",
"     <li>",
"      Reattach the syringe to the catheter and again aspirate for air to confirm that the catheter remains in the trachea.",
"     </li>",
"     <li>",
"      Hold the catheter firmly in place at all times or delegate an assistant to do this to reduce the chance of kinking or dislodgement, even after it has been secured with suture material.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h3\">",
"     Performing transtracheal ventilation",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Connect the catheter to high pressure tubing (connected to a valve and a source of 100 percent oxygen) or to a bag-valve-mask (",
"      <a class=\"graphic graphic_figure graphicRef52559 \" href=\"UTD.htm?27/49/28447\">",
"       figure 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef73064 \" href=\"UTD.htm?22/23/22899\">",
"       figure 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef76530 \" href=\"UTD.htm?9/12/9410\">",
"       figure 4",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef50969 \" href=\"UTD.htm?2/14/2273\">",
"       figure 5",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Bag-valve-mask connector options'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H22\">",
"       'Oxygen tubing connector options'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Give a few ventilations to reconfirm placement and ensure that the equipment is functioning properly.",
"     </li>",
"     <li>",
"      Fix the catheter in place with a suture or a tracheostomy tie, as possible.",
"     </li>",
"     <li>",
"      Interpose a capnometer in the circuit to monitor end tidal CO2, if possible.",
"     </li>",
"     <li>",
"      Begin regular ventilation by intermittently opening and closing the in-line valve (",
"      <a class=\"graphic graphic_figure graphicRef55816 \" href=\"UTD.htm?22/34/23078\">",
"       figure 6",
"      </a>",
"      ); by intermittently occluding the side port, y-connector, or stopcock (",
"      <a class=\"graphic graphic_figure graphicRef76530 \" href=\"UTD.htm?9/12/9410\">",
"       figure 4",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef50969 \" href=\"UTD.htm?2/14/2273\">",
"       figure 5",
"      </a>",
"      ); or by ventilations with the self-inflating resuscitation bag, depending on the system in use.",
"     </li>",
"     <li>",
"      Use I:E ratio of 1:4 to 1:5, with a breath rate of 10 to",
"      <span class=\"nowrap\">",
"       12/min",
"      </span>",
"      for most children. Change the ratio to 1:2 to 1:3 with a breath rate of 15 to",
"      <span class=\"nowrap\">",
"       20/min",
"      </span>",
"      in the setting of increased intracranial pressure to improve CO2 elimination. With partial or complete upper airway obstruction, use the ratio of 1:8 to 1:10 with a breath rate of 5 to",
"      <span class=\"nowrap\">",
"       6/min",
"      </span>",
"      to reduce the risk of pulmonary barotrauma. Adjust these ratios based on clinical monitoring, blood gas measurements, and chest radiography.",
"     </li>",
"     <li>",
"      Stand clear and observe universal precautions as oropharyngeal secretions may sometimes be expelled through the patient's mouth and nose with great force.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Cricothyroidotomy may also be performed rapidly and effectively using a modified Seldinger technique (wire-guided or catheter-over-needle technique). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/50/4905?source=see_link&amp;anchor=H20#H20\">",
"     \"Emergent surgical cricothyrotomy (cricothyroidotomy)\", section on 'Seldinger technique'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Barotrauma and catheter issues that prevent transtracheal ventilation are the two most commonly described complications of percutaneous transtracheal ventilation (PTV) (",
"    <a class=\"graphic graphic_table graphicRef66377 \" href=\"UTD.htm?31/52/32587\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16441/abstract/3,7,12,14,15,32\">",
"     3,7,12,14,15,32",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Subcutaneous emphysema can develop during cricothyroidotomy, securing of the catheter, PTV, or after removing the catheter [",
"      <a class=\"abstract\" href=\"UTD.htm?16/3/16441/abstract/3,14,49\">",
"       3,14,49",
"      </a>",
"      ]. Kinking or dislodgement of the transtracheal catheter may result in rapid accumulation of subcutaneous gas in the tissues. In addition, multiple attempts at catheter placement may allow gas to escape into the tissues from previous puncture sites. Techniques to prevent the development of subcutaneous emphysema include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Using kink-resistant Teflon&trade; catheters",
"     </li>",
"     <li>",
"      Assigning an individual to hold the catheter hub",
"     </li>",
"     <li>",
"      Utilizing a commercially available cricothyroidotomy catheter with attached flanges for securing the catheter (avoids kinking and misplacement)",
"     </li>",
"     <li>",
"      Placing a fingertip firmly over the puncture site and applying pressure for a few minutes to prevent air leak after catheter removal",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Subcutaneous emphysema after PTV typically resolves without intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16441/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pulmonary barotrauma may arise from an overly high respiratory rate that leads to insufficient time for passive exhalation and can cause lung hyperinflation, pneumothorax, and pneumomediastinum. These complications may also cause diminished venous return to the heart resulting in reduced cardiac output",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hypotension [",
"      <a class=\"abstract\" href=\"UTD.htm?16/3/16441/abstract/2,3,13,32,50\">",
"       2,3,13,32,50",
"      </a>",
"      ]. Pulmonary barotrauma is more likely in the setting of complete upper airway obstruction. Very slow breath rates (eg, 5 to 6",
"      <span class=\"nowrap\">",
"       breaths/minute)",
"      </span>",
"      and very long expiratory time (eg, I:E ratio of 1:8 to 1:10) are recommended to avoid barotrauma in this setting.",
"     </li>",
"     <li>",
"      In one series, PTV could not be accomplished in 6 of 29 (21 percent) emergency patients who required a rescue airway because of poor landmarks, catheter kinking, or inability to place the catheter in the trachea [",
"      <a class=\"abstract\" href=\"UTD.htm?16/3/16441/abstract/3\">",
"       3",
"      </a>",
"      ]. Proper training and the use of Teflon&trade; or commercially available cricothyroidotomy catheters are potential ways to improve the success rate for PTV. Varaday et al. have described an easily made model for teaching cricothyroidotomy to medical personnel using readily available materials in any operating room like a plastic tray, standard plastic breathing tubing, tape, and gauze [",
"      <a class=\"abstract\" href=\"UTD.htm?16/3/16441/abstract/51\">",
"       51",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other less common complications of needle cricothyroidotomy and PTV include damage to adjacent structures, bleeding, and infection (",
"    <a class=\"graphic graphic_table graphicRef66377 \" href=\"UTD.htm?31/52/32587\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16441/abstract/7,49,50,52\">",
"     7,49,50,52",
"    </a>",
"    ]. Although pulmonary aspiration may occur during PTV, in a canine model, it provided significant protection from aspiration relative to dogs with unprotected airways [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16441/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h1\">",
"     FOLLOW-UP CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prolonged percutaneous transtracheal ventilation (PTV) is associated with excessive inspiratory workload, hypercapnia, barotrauma, and catheter dislodgement with subcutaneous emphysema [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16441/abstract/3,7,53\">",
"     3,7,53",
"    </a>",
"    ]. Thus, a definitive airway (ie, endotracheal tube or tracheostomy) should be obtained as soon as possible after PTV is established. Emergent anesthesiology and otolaryngology consultation may be required, especially in patients with traumatic injury to the face",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    neck.",
"   </p>",
"   <p>",
"    In non-traumatic cases, intubation, with direct laryngoscopy or guided by endoscope, is successful in the majority of cases. Subsequent intubation may be easier as the high tracheal pressure from expiratory gases tends to open the previously collapsed glottis, improving visualization of the glottic opening. In addition, there is reduced operator stress and more time to visualize, and if needed, suction the glottic opening [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16441/abstract/3,54\">",
"     3,54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Definition",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Needle cricothyroidotomy involves passing an over-the-needle catheter through the cricothyroid membrane (",
"      <a class=\"graphic graphic_figure graphicRef52559 \" href=\"UTD.htm?27/49/28447\">",
"       figure 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definitions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Percutaneous transtracheal ventilation (PTV) is the delivery of oxygen to the lungs through an over-the-needle catheter using a high pressure gas source and is considered a form of conventional ventilation. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definitions'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h2\">",
"     Indications and contraindications",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The primary indication for needle cricothyroidotomy with PTV is inability to maintain the airway with noninvasive standard airway procedures (eg, bag-valve-mask ventilation, endotracheal intubation) or rescue procedures (eg, laryngeal mask airway). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Needle cricothyroidotomy with PTV is absolutely contraindicated when the airway is maintainable through noninvasive means. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Contraindications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In addition, needle cricothyroidotomy with PTV should",
"      <strong>",
"       not",
"      </strong>",
"      be performed when damage to the larynx, cricoid cartilage, or trachea preclude successful oxygenation and ventilation via a transtracheal catheter. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Contraindications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h2\">",
"     Preparation and procedure",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The cricothyroid membrane, as the name implies, is bound by the cricoid cartilage inferiorly and the thyroid cartilage superiorly (",
"      <a class=\"graphic graphic_figure graphicRef73518 \" href=\"UTD.htm?14/22/14696\">",
"       figure 1",
"      </a>",
"      ). The key anatomic landmarks are (from cephalad to caudad): hyoid cartilage, thyroid cartilage, cricothyroid membrane, cricoid cartilage, and the tracheal rings. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Anatomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Needle cricothyroidotomy and percutaneous transtracheal ventilation (PTV) can be performed using standard materials readily available in any hospital (",
"      <a class=\"graphic graphic_figure graphicRef52559 \" href=\"UTD.htm?27/49/28447\">",
"       figure 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef73064 \" href=\"UTD.htm?22/23/22899\">",
"       figure 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef76530 \" href=\"UTD.htm?9/12/9410\">",
"       figure 4",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef50969 \" href=\"UTD.htm?2/14/2273\">",
"       figure 5",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef55816 \" href=\"UTD.htm?22/34/23078\">",
"       figure 6",
"      </a>",
"      ). Commercial setups are also attainable. To ensure maximum effectiveness in a highly stressful emergent setting, the equipment for PTV, including all the necessary components, should be organized and immediately available. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Equipment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The tables and figure summarize the procedure (",
"      <a class=\"graphic graphic_table graphicRef63745 \" href=\"UTD.htm?7/33/7709\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef70963 \" href=\"UTD.htm?16/56/17288\">",
"       figure 7",
"      </a>",
"      ) and potential complications (",
"      <a class=\"graphic graphic_table graphicRef66377 \" href=\"UTD.htm?31/52/32587\">",
"       table 2",
"      </a>",
"      ) for needle cricothyroidotomy with PTV. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Preparation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H26\">",
"       'Procedure'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H35\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16441/abstract/1\">",
"      Jorden RC, Moore EE, Marx JA, Honigman B. A comparison of PTV and endotracheal ventilation in an acute trauma model. J Trauma 1985; 25:978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16441/abstract/2\">",
"      Cot&eacute; CJ, Eavey RD, Todres ID, Jones DE. Cricothyroid membrane puncture: oxygenation and ventilation in a dog model using an intravenous catheter. Crit Care Med 1988; 16:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16441/abstract/3\">",
"      Patel RG. Percutaneous transtracheal jet ventilation: a safe, quick, and temporary way to provide oxygenation and ventilation when conventional methods are unsuccessful. Chest 1999; 116:1689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16441/abstract/4\">",
"      Mutzbauer TS, Keul W, Bernhard M, et al. [Invasive techniques in emergency medicine. IV. Cricothyrotomy in emergency situations]. Anaesthesist 2005; 54:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16441/abstract/5\">",
"      Ihra G, Gockner G, Kashanipour A, Aloy A. High-frequency jet ventilation in European and North American institutions: developments and clinical practice. Eur J Anaesthesiol 2000; 17:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16441/abstract/6\">",
"      Cook TM, Nolan JP, Magee PT, Cranshaw JH. Needle cricothyroidotomy. Anaesthesia 2007; 62:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16441/abstract/7\">",
"      Mace SE, Khan N. Needle cricothyrotomy. Emerg Med Clin North Am 2008; 26:1085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16441/abstract/8\">",
"      Mutzbauer TS, Munz R, Helm M, et al. [Emergency cricothyrotomy--puncture or anatomical preparation? Peculiarities of two methods for emergency airway access demonstrated in a cadaver model]. Anaesthesist 2003; 52:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16441/abstract/9\">",
"      Sise MJ, Shackford SR, Cruickshank JC, et al. Cricothyroidotomy for long-term tracheal access. A prospective analysis of morbidity and mortality in 76 patients. Ann Surg 1984; 200:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16441/abstract/10\">",
"      Craven RM, Vanner RG. Ventilation of a model lung using various cricothyrotomy devices. Anaesthesia 2004; 59:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16441/abstract/11\">",
"      Chan TC, Vilke GM, Bramwell KJ, et al. Comparison of wire-guided cricothyrotomy versus standard surgical cricothyrotomy technique. J Emerg Med 1999; 17:957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16441/abstract/12\">",
"      Ravussin P, Bayer-Berger M, Monnier P, et al. Percutaneous transtracheal ventilation for laser endoscopic procedures in infants and small children with laryngeal obstruction: report of two cases. Can J Anaesth 1987; 34:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16441/abstract/13\">",
"      Benumof JL, Scheller MS. The importance of transtracheal jet ventilation in the management of the difficult airway. Anesthesiology 1989; 71:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16441/abstract/14\">",
"      Weymuller EA Jr, Pavlin EG, Paugh D, Cummings CW. Management of difficult airway problems with percutaneous transtracheal ventilation. Ann Otol Rhinol Laryngol 1987; 96:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16441/abstract/15\">",
"      Boyce JR, Peters GE, Carroll WR, et al. Preemptive vessel dilator cricothyrotomy aids in the management of upper airway obstruction. Can J Anaesth 2005; 52:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16441/abstract/16\">",
"      Ezri T, Szmuk P, Warters RD, et al. Difficult airway management practice patterns among anesthesiologists practicing in the United States: have we made any progress? J Clin Anesth 2003; 15:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16441/abstract/17\">",
"      Bork K, Siedlecki K, Bosch S, et al. Asphyxiation by laryngeal edema in patients with hereditary angioedema. Mayo Clin Proc 2000; 75:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16441/abstract/18\">",
"      Hinze JD, Barker JA, Jones TR, Winn RE. Life-threatening upper airway edema caused by a distal rattlesnake bite. Ann Emerg Med 2001; 38:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16441/abstract/19\">",
"      Neff CC, Pfister RC, Van Sonnenberg E. Percutaneous transtracheal ventilation: experimental and practical aspects. J Trauma 1983; 23:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16441/abstract/20\">",
"      Frame SB, Simon JM, Kerstein MD, McSwain NE Jr. Percutaneous transtracheal catheter ventilation (PTCV) in complete airway obstruction--a canine model. J Trauma 1989; 29:774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16441/abstract/21\">",
"      Stothert JC Jr, Stout MJ, Lewis LM, Keltner RM Jr. High pressure percutaneous transtracheal ventilation: the use of large gauge intravenous-type catheters in the totally obstructed airway. Am J Emerg Med 1990; 8:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16441/abstract/22\">",
"      Campbell CT, Harris RC, Cook MH, Reines HD. A new device for emergency percutaneous transtracheal ventilation in partial and complete airway obstruction. Ann Emerg Med 1988; 17:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16441/abstract/23\">",
"      deLisser EA, Muravchick S. Emergency transtracheal ventilation. Anesthesiology 1981; 55:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16441/abstract/24\">",
"      Smith RB, Babinski M, Klain M, Pfaeffle H. Percutaneous transtracheal ventilation. JACEP 1976; 5:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16441/abstract/25\">",
"      Ward KR, Menegazzi JJ, Yealy DM, et al. Translaryngeal jet ventilation and end-tidal PCO2 monitoring during varying degrees of upper airway obstruction. Ann Emerg Med 1991; 20:1193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16441/abstract/26\">",
"      Little CM, Parker MG, Tarnopolsky R. The incidence of vasculature at risk during cricothyroidostomy. Ann Emerg Med 1986; 15:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16441/abstract/27\">",
"      Bennett JD, Guha SC, Sankar AB. Cricothyrotomy: the anatomical basis. J R Coll Surg Edinb 1996; 41:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16441/abstract/28\">",
"      Navsa N, Tossel G, Boon JM. Dimensions of the neonatal cricothyroid membrane - how feasible is a surgical cricothyroidotomy? Paediatr Anaesth 2005; 15:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16441/abstract/29\">",
"      Nicholls SE, Sweeney TW, Ferre RM, Strout TD. Bedside sonography by emergency physicians for the rapid identification of landmarks relevant to cricothyrotomy. Am J Emerg Med 2008; 26:852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16441/abstract/30\">",
"      Jacoby, JJ, Hamelberg, W, Reed, JP, Gillespie, B. A simple technique for artificial respiration. Am J Physiol 1951; 167:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16441/abstract/31\">",
"      REED JP, KEMPH JP, HAMELBERG W, et al. Studies with transtracheal artificial respiration. Anesthesiology 1954; 15:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16441/abstract/32\">",
"      Jacobs HB, Smyth NP, Witorsch P. Transtracheal catheter ventilation: clinical experience in 36 patients. Chest 1974; 65:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16441/abstract/33\">",
"      Attia RR, Battit GE, Murphy JD. Transtracheal ventilation. JAMA 1975; 234:1152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16441/abstract/34\">",
"      Smith RB, Myers EN, Sherman H. Transtracheal ventilation in paediatric patients; case reports. Br J Anaesth 1974; 46:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16441/abstract/35\">",
"      Yealy DM, Plewa MC, Stewart RD. An evaluation of cannulae and oxygen sources for pediatric jet ventilation. Am J Emerg Med 1991; 9:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16441/abstract/36\">",
"      Marr JK, Yamamoto LG. Gas flow rates through transtracheal ventilation catheters. Am J Emerg Med 2004; 22:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16441/abstract/37\">",
"      Chong CF, Wang TL, Chang H. Percutaneous transtracheal ventilation without a jet ventilator. Am J Emerg Med 2003; 21:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16441/abstract/38\">",
"      Goldstein B, Shannon DC, Todres ID. Supercarbia in children: clinical course and outcome. Crit Care Med 1990; 18:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16441/abstract/39\">",
"      Yealy DM, Plewa MC, Reed JJ, et al. Manual translaryngeal jet ventilation and the risk of aspiration in a canine model. Ann Emerg Med 1990; 19:1238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16441/abstract/40\">",
"      Tran TP, Rhee KJ, Schultz HD, Carl ML. Gas exchange and lung mechanics during percutaneous transtracheal ventilation in an unparalyzed canine model. Acad Emerg Med 1998; 5:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16441/abstract/41\">",
"      Delaney WA, Kaiser RE Jr. Percutaneous transtracheal jet ventilation made easy. Anesthesiology 1991; 74:952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16441/abstract/42\">",
"      Scuderi PE, McLeskey CH, Comer PB. Emergency percutaneous transtracheal ventilation during anesthesia using readily available equipment. Anesth Analg 1982; 61:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16441/abstract/43\">",
"      American College of Emergency Physicians, American Academy of Pediatrics. Care of children in the emergency department: guidelines for preparedness. Ann Emerg Med 2001; 37:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16441/abstract/44\">",
"      Soto R, Mesa A. New intravenous catheter not suitable for trans-tracheal jet ventilation. Anesth Analg 2001; 92:1074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16441/abstract/45\">",
"      Boyce JR, Peters G. Vessel dilator cricothyrotomy for transtracheal jet ventilation. Can J Anaesth 1989; 36:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16441/abstract/46\">",
"      Thompson C, Halder S, Wimbush S. Effective ventilation following emergency needle cricothyroidotomy. Resuscitation 2007; 72:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16441/abstract/47\">",
"      Gaufberg SV, Workman TP. New needle cricothyroidotomy setup. Am J Emerg Med 2004; 22:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16441/abstract/48\">",
"      Tobias JD, Higgins M. Capnography during transtracheal needle cricothyrotomy. Anesth Analg 1995; 81:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16441/abstract/49\">",
"      Carden E, Calcaterra TC, Lechtman A. Pneumatocele of the larynx: a complication of percutaneous transtracheal ventilation. Anesth Analg 1976; 55:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16441/abstract/50\">",
"      Newlands SD, Makielski KH. Cervical osteomyelitis after percutaneous transtracheal ventilation and tracheotomy. Head Neck 1996; 18:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16441/abstract/51\">",
"      Varaday SS, Yentis SM, Clarke S. A homemade model for training in cricothyrotomy. Anaesthesia 2004; 59:1012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16441/abstract/52\">",
"      Fikkers BG, van Vugt S, van der Hoeven JG, et al. Emergency cricothyrotomy: a randomised crossover trial comparing the wire-guided and catheter-over-needle techniques. Anaesthesia 2004; 59:1008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16441/abstract/53\">",
"      Ooi R, Fawcett WJ, Soni N, Riley B. Extra inspiratory work of breathing imposed by cricothyrotomy devices. Br J Anaesth 1993; 70:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16441/abstract/54\">",
"      McLeod AD, Turner MW, Torlot KJ, et al. Safety of transtracheal jet ventilation in upper airway obstruction. Br J Anaesth 2005; 95:560.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6313 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-210.101.131.232-DB21B48F7E-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_3_16441=[""].join("\n");
var outline_f16_3_16441=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H37\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Needle cricothyroidotomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Surgical cricothyroidotomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Percutaneous transtracheal ventilation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Transtracheal jet ventilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CONTRAINDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Absolute",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Relative",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      PRECAUTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Complete upper airway obstruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      PHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      PREPARATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Patient counseling/informed consent",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Equipment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - General equipment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Catheter (large bore)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Bag-valve-mask connector options",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Oxygen tubing connector options",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - High pressure oxygen source",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Oxygen tubing or equivalent",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Manual in-line valve",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      PROCEDURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      General considerations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Site verification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Analgesia and sedation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Skin preparation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Method",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      - Needle cricothyroidotomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      - Performing transtracheal ventilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      FOLLOW-UP CARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Definition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      Indications and contraindications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      Preparation and procedure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6313\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6313|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/22/14696\" title=\"figure 1\">",
"      Percutaneous transtracheal ventilation anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/49/28447\" title=\"figure 2\">",
"      Percutaneous transtracheal ventilation catheter adapters",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?22/23/22899\" title=\"figure 3\">",
"      Endotracheal tube adapter",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/12/9410\" title=\"figure 4\">",
"      Percutaneous transtracheal ventilation Y connector",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/14/2273\" title=\"figure 5\">",
"      Percutaneous transtracheal ventilation stopcock",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?22/34/23078\" title=\"figure 6\">",
"      In-line percutaneous transtracheal ventilationcontrol valve",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/56/17288\" title=\"figure 7\">",
"      Percutaneous transtracheal ventilation procedure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6313|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/33/7709\" title=\"table 1\">",
"      Percutaneous transtracheal ventilation summary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/52/32587\" title=\"table 2\">",
"      Percutaneous transtracheal ventilation complications",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/6/7274?source=related_link\">",
"      Clinical features and diagnosis of the mucopolysaccharidoses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/50/4905?source=related_link\">",
"      Emergent surgical cricothyrotomy (cricothyroidotomy)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_3_16442="Overview of central catheters for acute and chronic hemodialysis access";
var content_f16_3_16442=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of central catheters for acute and chronic hemodialysis access",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/3/16442/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/3/16442/contributors\">",
"     Steven J Bander, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/3/16442/contributors\">",
"     Steve J Schwab, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/3/16442/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/3/16442/contributors\">",
"     Jeffrey S Berns, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/3/16442/contributors\">",
"     John F Eidt, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/3/16442/contributors\">",
"     Joseph L Mills, Sr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/3/16442/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/3/16442/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/3/16442/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 21, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemodialysis requires access to blood vessels capable of providing rapid extracorporeal blood flow. Immediate hemodialysis access should be straightforward, available for immediate use, and trouble-free in the short-term (days to weeks). A large bore non-tunneled catheter is most often used when an immediate need for hemodialysis arises (eg, acute kidney injury, thrombosed hemodialysis access, poisoning). A non-tunneled catheter can be placed for initiation of acute hemodialysis, or if dialysis for more than a week or so is likely, a cuffed, tunneled catheter can be used instead. Cuffed, tunneled catheters can also be placed for patients with chronic kidney disease who require dialysis, but who have not had permanent vascular access placed. Ideally, when permanent dialysis access is required, an arteriovenous hemodialysis fistula or graft is placed, and once the fistula or graft is successfully used, the catheter can be removed.",
"   </p>",
"   <p>",
"    The basic aspects of dialysis access catheters and complications associated with them will be reviewed here. An overview of central venous access and placement of catheters at specific sites is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/32/44553?source=see_link\">",
"     \"Overview of central venous access\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H79680952\">",
"    <span class=\"h1\">",
"     DIALYSIS CATHETERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The broad categories of catheters available for hemodialysis vascular access include non-tunneled and tunneled catheters. The basic principles governing the use of catheters for hemodialysis and the general features of non-tunneled and tunneled catheters are discussed below. Although many types of hemodialysis catheters are available, trials systematically comparing the various catheters to assess the performance of different materials and catheter shapes on delivered dialyzer blood flow rates and rates of infection or thrombosis are not available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H79682271\">",
"    <span class=\"h2\">",
"     Basic principles",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dialysis catheters usually have at least two lumens attached to two ports (blue and red). The blue port draws blood from the body (proximal opening[s]) and the red port returns the blood from the dialysis machine to the patient (the distal opening[s]). The proximal and distal catheter openings are separated by at least 2 cm to minimize direct flow between them during dialysis (ie, recirculation). The continuous blood path made possible by the dual lumen design allows rapid blood flows and a hemodialysis technique that does not require",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/14/38120?source=see_link\">",
"     \"Hemodialysis anticoagulation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Triple-lumen, non-tunneled dialysis catheters are also available to facilitate blood drawing and diminish the need for additional catheters. The third port is located between the red and blue ports and is available to draw blood and administer intravenous fluid or drugs. In a multicenter, prospective study of non-tunneled triple lumen hemodialysis catheters, blood-flow rates and infectious complications were similar for triple-lumen catheters compared with dual-lumen hemodialysis catheters [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16442/abstract/1\">",
"     1",
"    </a>",
"    ]. Triple lumen catheters are more commonly used in the acute inpatient setting.",
"   </p>",
"   <p>",
"    Compared with a typical catheter used for central venous access, the lumen of a dialysis catheter has a larger diameter to provide a high rate of flow. The flow rate that a catheter is capable of delivering is determined by Poiseuille&rsquo;s Law which states that resistance to flow in a tube is proportional to the length of the tube and inversely proportional to the fourth power of the radius. Higher viscosity (increasing hematocrit) also increases resistance. At the same negative pre-pump pressure, blood flows are consistently higher with right-sided internal jugular vein catheters compared with left-sided catheters [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16442/abstract/2\">",
"     2",
"    </a>",
"    ], due, in part, to additional resistance to flow from the two necessary bends and longer length of the catheter for left-sided access.",
"   </p>",
"   <p>",
"    The actual blood flow rate provided by the catheter is almost always lower than the rate displayed on the dialysis pump due to negative inflow pressures from tubing deformation within the roller pump segment. In our experience, we have found that catheter flows may be 20 to 30 percent lower than what is recorded by the pump when negative inflow pressure exceeds 200 mmHg.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Non-tunneled catheters",
"    </span>",
"    &nbsp;&mdash;&nbsp;Non-tunneled hemodialysis catheters are designed for short-term use and are the preferred catheter for immediate hemodialysis vascular access. Many different non-tunneled catheters are available and are composed of materials such as polyurethane, polyethylene, polyvinyl chloride, and medical grade silicone. The luminal diameter ranges from 1 to 2 mm and pump flow rates are 300 to 400",
"    <span class=\"nowrap\">",
"     mL/min.",
"    </span>",
"    For the same negative inflow pressure, lower hemoglobin (hematocrit) levels produce higher blood flows. (See",
"    <a class=\"local\" href=\"#H79682271\">",
"     'Basic principles'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    These catheters are relatively straightforward to insert. Most non-tunneled dialysis catheters have a conically-pointed tip and are relatively rigid at room temperature to facilitate insertion, but the catheter generally softens at body temperature to minimize the potential for vessel trauma. Because the more rigid material used in non-tunneled catheters can perforate through the veins or heart, verification of correct catheter tip positioning is essential. Non-tunneled catheters are usually short (9 to 20 cm) in length to ensure that the catheter tip does not extend into the right atrium [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16442/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H79682089\">",
"     'Catheter positioning'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The rigidity of the catheter makes insertion time slightly less by avoiding the use or need for an introducer sheath or possibly a soft tissue dilator, which are associated with an increased risk of blood loss and air embolism.",
"   </p>",
"   <p>",
"    Precurved catheters and curved extensions for non-tunneled catheters are available to minimize catheter kinking at the exit site from the skin. (See",
"    <a class=\"local\" href=\"#H79683300\">",
"     'Catheter malfunction'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H79683463\">",
"    <span class=\"h3\">",
"     Duration of use",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use-life of non-tunneled catheters varies with insertion site. Mechanical malfunction and infectious complications are the principle reasons for removing a non-tunneled dialysis catheter. In general, internal jugular and subclavian vein catheters are suitable for two to three weeks of use although longer periods have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16442/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Femoral catheters are generally limited to a single dialysis session in ambulatory patients, and three to seven days in bed-bound patients [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16442/abstract/5-8\">",
"     5-8",
"    </a>",
"    ]. Femoral catheters in ambulatory patients are removed after each dialysis session because of the issues of safety and difficulty maintaining the catheters which are prone to malposition and kinking.",
"   </p>",
"   <p>",
"    After two weeks, the rate of infection rises in both the femoral and internal jugular positions. In a study of 318 new hemodialysis catheter insertions, the risk of bacteremia with internal jugular vein and femoral vein hemodialysis catheters was examined during the first four weekly intervals after placement [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16442/abstract/9\">",
"     9",
"    </a>",
"    ]. During weekly intervals which consisted of the time of placement to the end of week one, two, three, and four, the incidences of bacteremia for a femoral vein catheter were 3, 11, 18 and 29 percent, respectively, and for the internal jugular site were 2, 5, 5, and 10 percent. Lower rates of catheter-related bacteremia have been reported with the use of various exit-site protocols and locking solutions. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Catheter infection'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Following catheter removal, firm pressure should be applied for at least one to two minutes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Tunneled catheters",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tunneled dialysis catheters are associated with lower rates of infectious complications compared with non-tunneled catheters [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16442/abstract/6,10\">",
"     6,10",
"    </a>",
"    ]. The larger lumen size of tunneled catheters also allows for greater blood flow rates (&gt;400",
"    <span class=\"nowrap\">",
"     cc/min)",
"    </span>",
"    than non-tunneled catheters",
"   </p>",
"   <p>",
"    Tunneled catheters are primarily used for intermediate or long-term (&gt;2 weeks) hemodialysis vascular access [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16442/abstract/11\">",
"     11",
"    </a>",
"    ]. Placement of a tunneled catheter rather than a non-tunneled catheter may be prudent for ambulatory patients diagnosed with acute kidney injury given that the duration of dialysis cannot be predicted [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16442/abstract/12\">",
"     12",
"    </a>",
"    ]. Although chronic hemodialysis using a permanent vascular access (ie, arteriovenous fistula) is preferred, some patients are poor candidates for arteriovenous access creation and will require a hemodialysis catheter long-term [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16442/abstract/13\">",
"     13",
"    </a>",
"    ]. For critically ill patients, other comorbidities and confounding factors need to be considered [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16442/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H791616603\">",
"     'Long-term catheters versus arteriovenous access'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Tunneled dialysis catheters are generally double lumen catheters with a polyester cuff generally positioned at the skin exit site that allows tissue ingrowth, sealing off the catheter tunnel. They are composed of silicone and other soft flexible polymers like thin polyurethane, which are less thrombogenic than the materials used in non-tunneled catheters. These catheters are blunt, soft, and flexible. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/32/44553?source=see_link&amp;anchor=H362076169#H362076169\">",
"     \"Overview of central venous access\", section on 'Tunneled'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A wide variety of tunneled catheters are available from multiple manufacturers. Catheters are available in a variety of configurations and tip designs including double D, coaxial, shotgun, step tip, and split-tip among others. The differing designs aim to increase blood flow, minimize recirculation and prevent catheter tip obstruction. Separation of the tips of the catheter can be achieved with a staggered tip design, use of a septum extruding beyond the openings, or splitting the catheter lumens distally. Some catheters are self-centering with a built-in curvature designed to push the tip of the catheter away from the wall of the vessel or heart chamber. Despite the wide variety of designs of tunneled hemodialysis catheters, each with its theoretical advantages and disadvantages, the few available randomized trials have failed to show the superiority of one catheter over another, particularly when the end-point is long-term functional survival [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16442/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H79683881\">",
"    <span class=\"h3\">",
"     Surface-coated catheters",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antimicrobial and antithrombogenic catheters appear to be effective in preventing intravascular catheter infections in the non-dialysis setting [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16442/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/53/31578?source=see_link&amp;anchor=H12#H12\">",
"     \"Prevention of intravascular catheter-related infections\", section on 'Central catheters'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some studies of antibiotic-bonded or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    -coated hemodialysis catheters have reported a decreased incidence of catheter-related infections in the short term [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16442/abstract/17,19-21\">",
"     17,19-21",
"    </a>",
"    ]. As an example, 130 patients were randomly assigned to a minocycline-rifampin coated catheter or a standard catheter [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16442/abstract/17\">",
"     17",
"    </a>",
"    ]. At a mean catheter use period of eight days, infections were markedly reduced in the group that received the antibiotic-coated catheter (0 versus 7). In two retrospective studies of 263 tunneled hemodialysis jugular catheters (139 heparin-coated and 124 uncoated), the frequency of catheter malfunction and overall catheter survival were similar for both studies [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16442/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. In one of the studies, coated catheters had a decreased frequency of catheter-related bacteremia [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16442/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, hemodialysis catheters are often required to remain in the patient for several months, which is a critical factor when determining the efficacy of a coating. Randomized trials are needed to demonstrate the longevity of the coating protection, which ideally should approximate the length of the intended catheter placement. Also, it is important to establish whether this effect remains in place in settings where infection preventive care is established and adhered to [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16442/abstract/22-24\">",
"     22-24",
"    </a>",
"    ]. In the absence of good data demonstrating long-term efficacy, we do not feel the additional cost for these catheters is justified.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1037144934\">",
"    <span class=\"h3\">",
"     Catheter life",
"    </span>",
"    &nbsp;&mdash;&nbsp;The overall survival of tunneled hemodialysis catheters is highly variable. Unassisted one-year use-life of tunneled hemodialysis catheters appears to be as low as 9 percent, but reports are not consistent [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16442/abstract/25\">",
"     25",
"    </a>",
"    ]. Secondary one-year use rates range between 25 to 93 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16442/abstract/26-30\">",
"     26-30",
"    </a>",
"    ]. One study found a 74 percent one-year and a 43 percent two-year catheter survival [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16442/abstract/28\">",
"     28",
"    </a>",
"    ]. A larger study of 623 Tesio&reg; catheters reported the one-year and three-year postplacement use-life of 78 and 44 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16442/abstract/29\">",
"     29",
"    </a>",
"    ]. In another study, one-year patency was 50 percent when the catheter was used as permanent access [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16442/abstract/30\">",
"     30",
"    </a>",
"    ]. Almost all catheter losses were due to bacteremia. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Catheter infection'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H791616603\">",
"    <span class=\"h1\">",
"     LONG-TERM CATHETERS VERSUS ARTERIOVENOUS ACCESS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arteriovenous hemodialysis access with a fistula or graft is more reliable than the use of central venous catheters in terms of recirculation, flow rates achieved and",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    delivered [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16442/abstract/31\">",
"     31",
"    </a>",
"    ]. As predicted by actual blood flow (measured by ultrasound dilution), matched controls using hemodialysis catheters required an approximately 20 percent increase in treatment time to achieve urea removal equivalent to arteriovenous fistulas. A larger catheter luminal diameter can help to achieve higher blood-flow rates and possibly increase solute clearance. Flow rates can be doubled if the catheter lumen diameter can be increased by only 19 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16442/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hemodialysis with long-term catheters compared with arteriovenous fistulas is associated with:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A relative risk of death that is twofold greater",
"     </li>",
"     <li>",
"      A relative risk of bacteremia that is at least sevenfold greater",
"     </li>",
"     <li>",
"      Increased rate of hospitalization",
"     </li>",
"     <li>",
"      A decreased likelihood of adequate dialysis",
"     </li>",
"     <li>",
"      An increased number of vascular access procedures.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although autogenous arteriovenous access is the ideal, in some situations, it is not an option. Prolonged use of hemodialysis catheters are justified in the following situations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      As a bridge device for hemodialysis while the patient is awaiting living-related kidney donor transplantation or maturation of an autologous fistula or graft, and peritoneal dialysis is not an option.",
"     </li>",
"     <li>",
"      For patients with unsuitable vascular anatomy who have exhausted all other options including peritoneal dialysis.",
"     </li>",
"     <li>",
"      When the creation of an arteriovenous access (fistula or graft) is not felt to be feasible or may place the patient at a significantly increased risk for complications (eg, high output cardiac failure, myocardial ischemic events, steal syndrome).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients older than 70 years of age with multiple comorbidities are at high risk for morbidity and mortality related to dialysis. A decision to place a fistula or a tunneled catheter as the primary access in older patients should be individualized; however, some patients older than 70 with multiple comorbidities may be better served with a catheter or graft versus a fistula. In one retrospective study, the 18-month survival was 50 percent for patients older than 70 compared with 74 percent for younger patients, with an average time to death of 13.1 months [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16442/abstract/33\">",
"     33",
"    </a>",
"    ]. Given their life-expectancy and knowing that it takes an average of six months for an autogenous fistula to mature, it may be acceptable to place a catheter as the primary access. However, an observational study suggests that the use of hemodialysis catheters in the elderly population has nearly twofold risk for all-cause, infection-related and cardiovascular mortality compared with age-matched controls using a fistula [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16442/abstract/34\">",
"     34",
"    </a>",
"    ]. In a multivariate analysis, the presence and number of comorbidities such as pulmonary, cerebrovascular and cardiovascular diseases had greater effects on mortality compared with age alone [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16442/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H79681577\">",
"    <span class=\"h1\">",
"     CATHETER PLACEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Catheters for dialysis access are placed in a manner that is similar to central catheter placement for other conditions. An overview of central venous access is presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/32/44553?source=see_link\">",
"     \"Overview of central venous access\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Bedside insertion using local anesthesia may be appropriate for non-tunneled dialysis catheters in patients not known to have prior venous thrombosis or vein cannulation. Patients who have had prior access benefit from ultrasound imaging prior to or as an adjunct to dialysis catheter placement. Confirmation of the catheter tip location can be documented using fluoroscopic or digital imaging prior to use.",
"   </p>",
"   <p>",
"    Tunneled catheters are almost exclusively placed with ultrasound and fluoroscopic guidance with local anesthesia and sedation in an angiographic suite or appropriately equipped operating room due to their larger caliber (14 to 16 French) and requirement for tip placement. Catheter malposition is a common problem (25 to 40 percent) when fluoroscopy is not used for guidance; accurate catheter positioning can be achieved in 95 to 100 percent of cases with fluoroscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16442/abstract/36\">",
"     36",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H79683300\">",
"     'Catheter malfunction'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H79681682\">",
"    <span class=\"h2\">",
"     Access site considerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with any central venous catheter, dialysis catheters can be inserted into any of the central veins such as the internal jugular vein, the femoral vein, or the subclavian vein [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16442/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. Associated large peripheral veins, such as the external jugular vein, can also be used. The choice of the vascular access site and catheter should be guided by the urgency of dialysis, type of dialysis, history of prior access, and the overall medical condition of the patient.",
"   </p>",
"   <p>",
"    The right internal jugular vein is the ideal vein for hemodialysis access (non-tunneled and tunneled) because the vein drains directly into the superior vena cava. Placement of catheters into the left internal jugular vein requires that the catheter make two right angles prior to reaching the superior vena cava (",
"    <a class=\"graphic graphic_figure graphicRef74801 \" href=\"UTD.htm?41/21/42324\">",
"     figure 1",
"    </a>",
"    ), which can cause difficulties during insertion and has a higher incidence of catheter dysfunction, particularly with non-tunneled catheters. (See",
"    <a class=\"local\" href=\"#H79683300\">",
"     'Catheter malfunction'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Although hemodialysis catheters are most commonly placed into the internal jugular vein, the external jugular can also be used for tunneled catheters, and, with caution, for non-tunneled catheters. The external jugular vein usually enters into the subclavian vein at a right angle that is not easily negotiated by the stiffer short-term hemodialysis catheters, and perforation of the subclavian vein can occur.",
"   </p>",
"   <p>",
"    The subclavian vein can also be used for tunneled catheters if the jugular veins are occluded; however, this site has a high incidence (15 to 50 percent) of subclavian vein stenosis and subclavian vein thrombosis, and in general, subclavian vein insertion sites should be avoided [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16442/abstract/39\">",
"     39",
"    </a>",
"    ]. Subclavian",
"    <span class=\"nowrap\">",
"     stenosis/thrombosis",
"    </span>",
"    also compromises the placement of permanent ipsilateral upper extremity arteriovenous hemodialysis access [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16442/abstract/40\">",
"     40",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Central vein stenosis/thrombosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Common femoral vein hemodialysis catheter insertion may be needed, particularly in the setting of bilateral occlusion of the central thoracic veins [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16442/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. Venous access at the common femoral vein avoids many of the complications associated with thoracic central venous access (eg, pneumothorax, air embolism) and may be more appropriate in patients with certain medical comorbidities. As an example, femoral venous access is better tolerated in dyspneic patients and other patients (eg, morbidly obese) who are not able to lie flat for an extended period of time.",
"   </p>",
"   <p>",
"    A longer catheter is needed when hemodialysis access is placed into the common femoral vein. Short hemodialysis catheters (&lt;15 cm) have higher recirculation rates when the tip of the catheter is positioned in the iliac vein [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16442/abstract/43\">",
"     43",
"    </a>",
"    ]. A catheter length &gt;20 cm (tip to hub) is adequate for most average-sized adults to position the tip of the catheter in the inferior vena cava, which minimizes recirculation. However, very long catheters &gt;35 cm should be avoided, as flow rate decreases with increasing catheter length.",
"   </p>",
"   <p>",
"    In the presence of occlusion of above-mentioned veins, percutaneous translumbar insertion of the catheter into the inferior vena cava can be performed. Another approach uses open surgery to place a catheter directly into the right atrium, superior vena cava, inferior vena cava, or azygos vein. In cases of complete occlusion or obliteration of femoral and central",
"    <span class=\"nowrap\">",
"     (neck/thoracic)",
"    </span>",
"    veins, the femoral artery can be used for access if immediate access is required [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16442/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H79681689\">",
"    <span class=\"h2\">",
"     Technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemodialysis catheters are inserted percutaneously using a modified Seldinger guide-wire technique. An anatomic landmark-based approach can be used, but catheter placement with ultrasound guidance is recommended. Technical success and reduced rates of access-related complications correlate with experience and the use of ultrasound guidance. &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/11/36024?source=see_link\">",
"     \"Placement of femoral venous catheters\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/14/3306?source=see_link\">",
"     \"Placement of jugular venous catheters\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/27/1466?source=see_link\">",
"     \"Placement of subclavian venous catheters\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/47/3833?source=see_link\">",
"     \"Principles of ultrasound-guided venous access\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Preventing infection related to hemodialysis catheters requires adherence to proper technique and optimal catheter management [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16442/abstract/11,45\">",
"     11,45",
"    </a>",
"    ]. Measures to minimize dialysis catheter infection, including the use of antimicrobial agents at the exit site, antibiotic lock solutions, and eradicating nasal carriage, are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/8/29834?source=see_link&amp;anchor=H24#H24\">",
"     \"Tunneled, cuffed hemodialysis catheter-related bacteremia\", section on 'Prevention'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For tunneled catheters, the insertion technique varies depending upon the type of catheter. In general, tunneling the catheter follows venous puncture and guidewire placement. Because of the large diameter of hemodialysis catheters, a valved introducer peel-away sheath is needed to deliver the catheter into the vessel after dilation of the overlying soft tissues. The dilators and sheaths are stiff and should be imaged during their placement using fluoroscopy to ensure that the tip of the dilator is not taking an aberrant path, deforming the wire, or pushing through the vessel. &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/32/44553?source=see_link&amp;anchor=H177534144#H177534144\">",
"     \"Overview of central venous access\", section on 'Tunneled catheters'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H79681696\">",
"    <span class=\"h3\">",
"     Ultrasound guidance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Real-time ultrasound guidance is recommended for venous access during the placement of central venous catheters. Appropriate training is required to effectively utilize ultrasound devices. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/47/3833?source=see_link\">",
"     \"Principles of ultrasound-guided venous access\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Ultrasound is used to assess vein size and patency prior to venous puncture, and ultrasound guidance during venipuncture minimizes the incidence of venous access-related complications, decreases procedure time, and increases the rate of initial technical success [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16442/abstract/46-49\">",
"     46-49",
"    </a>",
"    ]. Ultrasound-guided venous access also decreases the likelihood of arterial puncture or pneumothorax in patients undergoing hemodialysis catheter placement [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16442/abstract/46,50-53\">",
"     46,50-53",
"    </a>",
"    ]. A metaanalysis found significantly decreased risks of catheter placement failure (relative risk [RR], 0.12; 95% CI 0.04-0.37), failure to place catheter on first attempt (RR, 0.40; 95% CI 0.29-0.56), arterial punctures (RR, 0.22; 95% CI 0.06-0.81), and hematoma formation (RR, 0.27; 95% CI 0.08-0.88) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16442/abstract/54\">",
"     54",
"    </a>",
"    ]. Another advantage of an ultrasound-guided technique in placing internal jugular hemodialysis catheters is an ability to place the access in more caudally, which may reduce kinking; a minimal degree of kinking can severely diminish flow rates.",
"   </p>",
"   <p>",
"    The use of ultrasound to guide the path of jugular or subclavian hemodialysis catheters is hampered by poor visualization across the chest wall, but ultrasound alone may be appropriate to guide the placement of common femoral catheters in selected individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16442/abstract/55\">",
"     55",
"    </a>",
"    ]. Using ultrasound to assess for complications such as pneumothorax following catheter placement has been reported. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/32/44553?source=see_link&amp;anchor=H177533298#H177533298\">",
"     \"Overview of central venous access\", section on 'Use of ultrasound'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H79682089\">",
"    <span class=\"h3\">",
"     Catheter positioning",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to the use of a central catheter for hemodialysis, the positioning of the tip of the catheter needs to be verified, typically using fluoroscopy or digital imaging. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/32/44553?source=see_link&amp;anchor=H1232392311#H1232392311\">",
"     \"Overview of central venous access\", section on 'Confirmation of catheter tip positioning'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Ideal positioning of hemodialysis access catheters is as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The tip of non-tunneled jugular hemodialysis catheters should be positioned in the superior vena cava. Because of the stiffness of short-term access catheters and risk for complications, atrial placement should be avoided [",
"      <a class=\"abstract\" href=\"UTD.htm?16/3/16442/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The tip of tunneled catheters should be at the junction of the superior vena cava and right atrium. However, location of the tip in the right atrium in the supine position is permissible due to the catheter&rsquo;s soft polymer construction and the tendency in the upright position for the catheter to retract 2 to 4 cm into the superior vena cava or brachiocephalic vein (particularly in women and barrel-chested men), which can lead to a catheter malfunction.",
"     </li>",
"     <li>",
"      The tip of femoral hemodialysis catheters (non-tunneled or tunneled) should be placed in the distal inferior vena cava to minimize recirculation. Catheters that are located in the iliac veins should be repositioned.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H79683083\">",
"    <span class=\"h2\">",
"     Anticoagulants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prophylaxis against catheter thrombosis is important and needs to begin at the time of catheter insertion and usage. General issues related to the use of anticoagulant flush solutions for central catheters are discussed elsewhere. Issues relevant to hemodialysis catheters are reviewed below. (See",
"    <a class=\"local\" href=\"#H79683300\">",
"     'Catheter malfunction'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    To prevent thrombus formation within the catheter, proper flushing and the instillation of an anticoagulant into each lumen decreases, but does not eliminate, the risk of hemodialysis catheter thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16442/abstract/18,56-58\">",
"     18,56-58",
"    </a>",
"    ]. After catheter placement and after each use, the catheter should first be flushed with saline to evacuate any residual blood. Each lumen of the catheter is then filled with a 1:100 (1 mL = 100 Units) or 1:1000 (1 mL = 1000 Units)",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    solution. In past practice, more concentrated heparin (1:5000, 1:10,000) was used but was associated with inadvertent anticoagulation, particularly if the catheter lumen was overfilled [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16442/abstract/58\">",
"     58",
"    </a>",
"    ]. Overfilling the catheter lumen by as little as 0.1 cc could result in a heparin bolus of 500 to 1000 units. These higher concentrations have been abandoned.",
"   </p>",
"   <p>",
"    The fill volume of each tunneled catheter lumen is found on each port, imprinted on the side of the catheter or clamp [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16442/abstract/59\">",
"     59",
"    </a>",
"    ]. At a lower",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    concentration (1:100 or 1:1000), each lumen of the catheter is filled with the amount specified by the manufacturer on the port plus an additional 0.1 to 0.2 cc. Sodium citrate 4% can also be used [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16442/abstract/58,60,61\">",
"     58,60,61",
"    </a>",
"    ]. Typical volumes are 1.2 to 1.8 mL for short non-tunneled catheters and 1.9 to 3.1 mL for larger tunneled catheters.",
"   </p>",
"   <p>",
"    Randomized trials suggest that the instillation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    (recombinant tissue-type plasminogen activator, rt-PA), rather than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    , may improve catheter blood flow and decrease the incidence of catheter clotting [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16442/abstract/62-65\">",
"     62-65",
"    </a>",
"    ]. In one of these studies, 225 patients were randomly assigned to a catheter locking regimen of recombinant tissue (rt-PA) or heparin [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16442/abstract/64\">",
"     64",
"    </a>",
"    ]. Significantly lower rates of catheter malfunction (20 versus 35 percent) and catheter-related bacteremia (4.5 versus 13 percent) were seen in those who received rt-PA. In a crossover trial of 12 patients, the administration of alteplase (2 mg injected into each lumen) was associated with significantly higher blood flow rates and better arterial and venous pressures compared with heparin [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16442/abstract/62\">",
"     62",
"    </a>",
"    ]. No episodes of catheter thrombosis occurred with alteplase, compared with 20 percent of the patients when using heparin.",
"   </p>",
"   <p>",
"    Some anecdotal evidence suggests that chronic systemic anticoagulation with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    or low molecular-weight",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    prevents hemodialysis catheter thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16442/abstract/11\">",
"     11",
"    </a>",
"    ]; however, there may be an increased risk of bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16442/abstract/66\">",
"     66",
"    </a>",
"    ]. Overall, the currently available data does not support routine systemic antithrombotic prophylaxis for hemodialysis catheters. The use of anticoagulants to prevent catheter-related upper extremity deep vein thrombosis is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/48/7942?source=see_link&amp;anchor=H4#H4\">",
"     \"Strategies other than treatment of stenosis to prevent thrombosis of hemodialysis vascular access grafts\", section on 'Systemic anticoagulation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/26/27050?source=see_link&amp;anchor=H32#H32\">",
"     \"Catheter-induced upper extremity venous thrombosis\", section on 'Thrombosis prevention'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     DIALYSIS CATHETER COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of complications are associated with the placement and use of hemodialysis access catheters, including those associated with catheter insertion and longer-term (&gt;1 week) complications such as catheter malfunction, central vein stenosis or thrombosis and catheter infection [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16442/abstract/67\">",
"     67",
"    </a>",
"    ]. The number and severity of the complications increases with multiple catheter implantations and a longer catheter dwelling time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Insertion or immediate access-related",
"    </span>",
"    &nbsp;&mdash;&nbsp;The nature of access-related catheter complications depends upon the site of insertion. Access-related complications for hemodialysis catheter placement are similar to those seen with the placement of other non-tunneled and tunneled central catheters. However, because of the larger bore of hemodialysis catheters, the severity of the complications may be worse. General complications of central venous access are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/1/29?source=see_link\">",
"     \"Complications of central venous catheters and their prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For hemodialysis catheters, access-related complication rates are lowest for the femoral position, and complications, when they occur at this site, tend to be minor. The main complication associated with hemodialysis access is inadvertent needle puncture of the associated artery (eg, common femoral artery, subclavian artery, carotid artery). Bleeding usually resolves within 10 to 15 minutes with direct digital compression, which is easily performed at the femoral and jugular sites. Ultrasound-guided puncture of the common femoral vein and other venous access sites reduces complication rates and increases technical success, and should be used whenever available [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16442/abstract/36,47-49\">",
"     36,47-49",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H79681696\">",
"     'Ultrasound guidance'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Unrecognized arterial laceration can lead to massive bleeding into the thigh, retroperitoneum, or chest depending upon the access site [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16442/abstract/68\">",
"     68",
"    </a>",
"    ]. Inadvertent catheterization of an artery with the large bore hemodialysis catheter should prompt consultation with a vascular surgeon. Removal of the catheter should not be attempted in the absence of surgical consultation.",
"   </p>",
"   <p>",
"    Pneumothorax is another serious and potentially life-threatening complication. The internal jugular approach is associated with a lower risk of pneumothorax compared with a subclavian approach. The rate of pneumothorax for hemodialysis catheter placement ranges from 0 to 6 percent but has been reported to be as high as 12.4 percent for less experienced practitioners [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16442/abstract/36,46-48,52,53\">",
"     36,46-48,52,53",
"    </a>",
"    ]. An initial failed vein cannulation is also associated with an increased risk of pneumothorax. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/1/29?source=see_link\">",
"     \"Complications of central venous catheters and their prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Air embolism is a rare but potentially lethal complication associated with jugular and subclavian insertion. Small air emboli probably occur more often than recognized. Various maneuvers during insertion can be used to minimize the risk, such as crimping the introducer sheath before catheter insertion, asking the patient to hum to avoid large inspiratory efforts during insertion, or using a valved sheath. Air embolism can also occur with catheter removal. Central venous catheters should be removed with the patient supine or in slight Trendelenburg position, and the entry site covered with an occlusive dressing. The proper positioning and techniques for insertion and removal of central catheters are discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/1/29?source=see_link\">",
"     \"Complications of central venous catheters and their prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If air embolism has occurred, the patient should be placed in the left lateral decubitus position with 100 percent oxygen administered. The treatment of air embolism is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/48/38664?source=see_link&amp;anchor=H10#H10\">",
"     \"Air embolism\", section on 'Clinical features'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/48/38664?source=see_link&amp;anchor=H18#H18\">",
"     \"Air embolism\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H79683300\">",
"    <span class=\"h2\">",
"     Catheter malfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adequate catheter function is the ability to sustain a blood flow rate of greater than 300",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16442/abstract/69\">",
"     69",
"    </a>",
"    ]. Using this criterion, 87 percent of tunneled catheters will have dysfunction at least once during their use [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16442/abstract/30\">",
"     30",
"    </a>",
"    ]. Dysfunction severe enough to require catheter replacement complicates 16 percent of catheters for a rate of 0.58 exchanges per catheter-year depending on catheter type [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16442/abstract/70\">",
"     70",
"    </a>",
"    ]. An alternative measure of catheter dysfunction is catheter reliability defined as the proportion of dialysis treatments in which the catheter provided adequate blood flows. One study, for example, found that catheters provided blood flow &lt;350",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    in 13 to 58 percent of dialysis treatments [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16442/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A mechanical malfunction of a hemodialysis catheter is often suspected when blood cannot be withdrawn from the catheter, or saline cannot be infused into it. Low flow rates and high pressures during dialysis may indicate an impending occlusion. The mechanism of the obstruction may be mechanical (kinking of the catheter, tight suture, catheter pushed against the vessel wall), or thrombotic. Differentiating between a mechanical or thrombotic etiology cannot usually be made on clinical grounds and a radiograph should be obtained to detect catheter malposition.",
"   </p>",
"   <p>",
"    Non-tunneled hemodialysis catheters may be more susceptible to mechanical complications compared with tunneled catheters. However, there are limited data discussing the removal of malfunctioning non-tunneled catheters for reasons beyond infection. In two studies, the incidence of low flow in non-tunneled hemodialysis catheters thought to be due to mechanical obstruction from malposition or kinking, or intracatheter obstruction by thrombus or fibrin sheath ranged from 19 to 30 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16442/abstract/6,10\">",
"     6,10",
"    </a>",
"    ]. Disruption of fibrin sheaths at the time of catheter exchange for dysfunction reduces dysfunction in the newly placed catheter [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16442/abstract/71\">",
"     71",
"    </a>",
"    ]. The use of thrombolytic therapy for catheter lysis as described for other central venous catheters is very useful for treating hemodialysis catheter thrombosis. As an example, 2 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    was placed into each port of 22 nonfunctional tunneled hemodialysis catheters [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16442/abstract/72\">",
"     72",
"    </a>",
"    ]. Adequate blood flow rates (&ge;200",
"    <span class=\"nowrap\">",
"     mL/min)",
"    </span>",
"    were established in nearly 90 percent (49 of 56) of cases. Thrombolysis of chronic hemodialysis vascular access is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/22/15722?source=see_link&amp;anchor=H16#H16\">",
"     \"Thrombosis associated with chronic hemodialysis vascular access: Catheters\", section on 'Intraluminal lytic enzyme'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Central vein stenosis/thrombosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a correlation between central venous cannulation and the development of central vein stenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16442/abstract/73\">",
"     73",
"    </a>",
"    ]. Progressive vein stenosis ultimately leads to venous thrombosis. In one study of 57 patients following dialysis catheter placement, 28 percent of patients developed central vein thrombus, and 14 percent developed brachiocephalic vein stenosis at a mean of 21 days (range 7 to 59 days) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16442/abstract/74\">",
"     74",
"    </a>",
"    ]. The odds of a central vein stenosis increase by 38 percent with each additional catheter placement.",
"   </p>",
"   <p>",
"    Venous cannulation creates an area of vessel injury which, upon healing, leads to an area of fibrosis. Repeated cannulation at the same site reinjures the vessel. Points within the vessel that are repetitively chafed by the catheter may also be injured [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16442/abstract/75\">",
"     75",
"    </a>",
"    ]. In addition, the rapid blood flows associated with hemodialysis create areas of turbulent flow beyond the tip of the catheter which stimulates endothelial proliferation, potentially leading to venous stenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16442/abstract/73\">",
"     73",
"    </a>",
"    ]. Stagnation of flow at the catheter insertion site can also occur if the diameter of the catheter is large relative to the diameter of the cannulated vessel. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/26/27050?source=see_link&amp;anchor=H165302905#H165302905\">",
"     \"Catheter-induced upper extremity venous thrombosis\", section on 'Catheter-related factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In observational studies of the venous access sites discussed above, central vein",
"    <span class=\"nowrap\">",
"     stenosis/thrombosis",
"    </span>",
"    is more frequent with subclavian hemodialysis catheters compared with internal jugular vein catheters (15 to 50 percent versus 10 to 27 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16442/abstract/40,75,76\">",
"     40,75,76",
"    </a>",
"    ]. In a study of tunneled femoral vein catheters, ipsilateral lower extremity deep vein thrombosis developed at a rate of 26 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16442/abstract/42\">",
"     42",
"    </a>",
"    ]. The relatively straight course of jugular and femoral catheters, in part, explains their lower rates of stenosis and thrombosis. Because of the implication of catheter",
"    <span class=\"nowrap\">",
"     stenosis/thrombosis",
"    </span>",
"    for future permanent upper extremity arteriovenous fistula creation, we agree with the updated 2006",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    guidelines that suggest avoiding placement in the subclavian vein, unless no other site is available [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16442/abstract/77,78\">",
"     77,78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most central vein stenoses are initially asymptomatic, but the stenosis may manifest after the creation of a peripheral arteriovenous fistula in the ipsilateral extremity. Symptoms consist of edema and elevated venous pressure on dialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16442/abstract/73\">",
"     73",
"    </a>",
"    ]. The high flow into the accessed vessel exceeds the rate at which blood can flow across the stenotic lesion, leading to venous congestion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/26/27050?source=see_link&amp;anchor=H11#H11\">",
"     \"Catheter-induced upper extremity venous thrombosis\", section on 'Clinical presentation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Central vein thrombosis usually responds to anticoagulation or thrombolytic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16442/abstract/73\">",
"     73",
"    </a>",
"    ]. Percutaneous transluminal angioplasty can be performed to dilate areas of stenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16442/abstract/79\">",
"     79",
"    </a>",
"    ]. Lesions that recur following angioplasty can be treated with metal stents. However, the natural history of treated central vein stenosis associated with hemodialysis catheters is not favorable, as most vessels ultimately become partially or fully occluded. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/22/15722?source=see_link\">",
"     \"Thrombosis associated with chronic hemodialysis vascular access: Catheters\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/37/18010?source=see_link\">",
"     \"Percutaneous angioplasty for the treatment of venous stenosis affecting hemodialysis access grafts\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Catheter infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The infections associated with temporary hemodialysis catheters include local exit site infection and systemic bacteremia. The majority of bacteremias among hemodialysis patients are caused by hemodialysis catheters. The risk of bacteremia with tunnel cuffed catheters averages 2.3 per 1000 catheter days, which translates into an approximate 20 to 25 percent risk over the average duration of use [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16442/abstract/26,80\">",
"     26,80",
"    </a>",
"    ]. The bacteremia rate ranges from 0.1 to 5.5 per 1000 catheter days in prospective studies of tunneled catheters [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16442/abstract/26,80\">",
"     26,80",
"    </a>",
"    ]. Catheter-associated bacteremia is associated with a 22 to 38 percent rate of metastatic infectious complications or death [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16442/abstract/81\">",
"     81",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/8/29834?source=see_link\">",
"     \"Tunneled, cuffed hemodialysis catheter-related bacteremia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Bacteremia generally results from contamination of the catheter lumen or migration of bacteria from skin puncture site [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16442/abstract/5,37,38,82,83\">",
"     5,37,38,82,83",
"    </a>",
"    ]. This migration usually limits the duration of use of non-tunneled catheters [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16442/abstract/82\">",
"     82",
"    </a>",
"    ]. Skin flora, Staphylococcus and Streptococcus species, are responsible for the majority of infections [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16442/abstract/83\">",
"     83",
"    </a>",
"    ]. The risk of infection with tunneled catheters is significantly reduced because the cuff, which is usually positioned just proximal to the catheter exit site, serves as a barrier to the migration of bacteria from the skin.",
"   </p>",
"   <p>",
"    The rate of infection may vary with the site of catheter insertion. Some feel that the highest risk is with femoral catheters, followed by jugular and then subclavian vein catheters. However, there is conflicting evidence concerning the risk of infection based upon the site of insertion.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 105 non-tunneled hemodialysis catheters (79 subclavian and 26 jugular), a significantly higher risk of catheter-related bacteremia was associated with internal jugular access (hazard ratio 3.57) compared with subclavian venous access [",
"      <a class=\"abstract\" href=\"UTD.htm?16/3/16442/abstract/84\">",
"       84",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another study of 318 new hemodialysis catheters, a significantly higher risk of bacteremia was seen after insertion into the femoral vein compared with internal jugular vein placement (relative risk 3.0) [",
"      <a class=\"abstract\" href=\"UTD.htm?16/3/16442/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In contrast, a large trial in which 750 dialysis patients were randomly assigned to receive short-term jugular or femoral venous access, no significant differences in infection rates were found for jugular and femoral venous catheterization (2.3 versus 1.5 per 1000 infections per catheter-days, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?16/3/16442/abstract/85\">",
"       85",
"      </a>",
"      ]. However, among obese patients (BMI &gt;28.4), the incidence of catheter colonization was significantly lower with jugular catheterization, but there was no difference in rates of clinical infection. In addition, hematomas were significantly more common with jugular catheterization (3.6 versus 1.1 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For non-tunneled catheters, the development of exit-site infection or bacteremia requires",
"    <strong>",
"     prompt removal",
"    </strong>",
"    of the catheter and appropriate intravenous antibiotic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/3/16442/abstract/9,39,86\">",
"     9,39,86",
"    </a>",
"    ]. Exit-site infections associated with tunneled catheters may respond to antibiotics alone and catheter removal may not be needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9380285\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There are two main types of hemodialysis catheters; non-tunneled or tunneled. Non-tunneled catheters are shorter in length and are relatively stiff, which facilitates insertion. Tunneled dialysis catheters are made of soft polymer catheters and have one to two cuffs around the catheter to promote tissue growth and adherence, and to prevent migration of bacteria along the catheter to minimize the risk of catheter infection. Faster blood flow rates are achieved during dialysis for tunneled catheters because of their larger luminal diameter compared with non-tunneled catheters. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Non-tunneled hemodialysis catheters are preferred for immediate and acute hemodialysis. Because of the increased risk of infection over time, the duration of use for non-tunneled catheters is limited, usually less than two weeks for internal jugular catheters. For femoral catheters, use is generally limited to a single treatment in ambulatory patients, but in bed-bound hospitalized patients, the catheter may remain in place for three to seven days. (See",
"      <a class=\"local\" href=\"#H79680952\">",
"       'Dialysis catheters'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although autogenous arteriovenous access is ideal, in some situations, it is not an option. Prolonged use of hemodialysis catheters is justified when needed as a bridge device while awaiting transplant or arteriovenous access maturation, for patients who have exhausted other forms of access, and when the risk of complications of arteriovenous access is excessive. Tunneled catheters that are used for intermediate or long-term vascular hemodialysis access generally function for 6 to 12 months. (See",
"      <a class=\"local\" href=\"#H791616603\">",
"       'Long-term catheters versus arteriovenous access'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1037144934\">",
"       'Catheter life'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Dialysis catheters are inserted using a modified Seldinger guide-wire technique, typically into the jugular or femoral vein. We agree with the",
"      <span class=\"nowrap\">",
"       K/DOQI",
"      </span>",
"      guidelines that suggest avoiding hemodialysis access in the subclavian vein, unless no other option is available. Subclavian access is associated with a high incidence of subclavian vein stenosis and thrombosis, which impairs the function of the catheter and compromises subsequent permanent arteriovenous dialysis access. (See",
"      <a class=\"local\" href=\"#H79681682\">",
"       'Access site considerations'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Central vein stenosis/thrombosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Access-related complications vary with the site. The main access-related complication is inadvertent needle puncture of the associated artery (eg, common femoral artery, subclavian artery, carotid artery), which can be reduced by using ultrasound guidance during vein cannulation. Fluoroscopy should be used when placing tunneled catheters during guide-wire insertion, and dilator, sheath, and catheter manipulation. Inadvertent catheterization of the artery instead of vein with a large-bore hemodialysis catheter should prompt consultation with a vascular surgeon. Other complications of thoracic central venous access include pneumothorax, and, more rarely, atrial or vena caval perforation. Internal jugular insertion is associated with a lower risk of pneumothorax compared with subclavian access. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Insertion or immediate access-related'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H79681696\">",
"       'Ultrasound guidance'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H79682089\">",
"       'Catheter positioning'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Thrombosis of the lumen of the hemodialysis catheter frequently complicates its use. Thrombus formation can be prevented by instilling each catheter lumen with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      or sodium citrate after catheter placement, and following each hemodialysis session. (See",
"      <a class=\"local\" href=\"#H79683083\">",
"       'Anticoagulants'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H79683300\">",
"       'Catheter malfunction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Central vein",
"      <span class=\"nowrap\">",
"       stenosis/thrombosis",
"      </span>",
"      is a complication of all central venous catheters but may be more prominent with hemodialysis access due to stagnation of flow (larger diameter of the catheter relative to the cannulated vein), repeated catheterizations, and turbulent blood flow during dialysis. Central vein",
"      <span class=\"nowrap\">",
"       stenosis/thrombosis",
"      </span>",
"      is more common following subclavian compared with jugular venous hemodialysis access. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Central vein stenosis/thrombosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Infectious complications of hemodialysis catheters include local exit site infection and systemic bacteremia. The risk of infection for tunneled catheters is significantly lower compared with non-tunneled catheters. For non-tunneled hemodialysis catheters, exit site infection or bacteremia should prompt immediate removal of the catheter; however, for tunneled catheters, exit site infections can often be treated locally with oral or intravenous antibiotics and local wound care. Prevention of infection involves adherence to proper placement technique, and optimal catheter management. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Catheter infection'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H79681689\">",
"       'Technique'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16442/abstract/1\">",
"      Contreras G, Liu PY, Elzinga L, et al. A multicenter, prospective, randomized, comparative evaluation of dual- versus triple-lumen catheters for hemodialysis and apheresis in 485 patients. Am J Kidney Dis 2003; 42:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16442/abstract/2\">",
"      Oliver MJ, Edwards LJ, Treleaven DJ, et al. Randomized study of temporary hemodialysis catheters. Int J Artif Organs 2002; 25:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16442/abstract/3\">",
"      Shamir MY, Bruce LJ. Central venous catheter-induced cardiac tamponade: a preventable complication. Anesth Analg 2011; 112:1280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16442/abstract/4\">",
"      Ponikvar R, Buturovi-Ponikvar J. Temporary hemodialysis catheters as a long-term vascular access in chronic hemodialysis patients. Ther Apher Dial 2005; 9:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16442/abstract/5\">",
"      Cheesbrough JS, Finch RG, Burden RP. A prospective study of the mechanisms of infection associated with hemodialysis catheters. J Infect Dis 1986; 154:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16442/abstract/6\">",
"      Weijmer MC, Vervloet MG, ter Wee PM. Compared to tunnelled cuffed haemodialysis catheters, temporary untunnelled catheters are associated with more complications already within 2 weeks of use. Nephrol Dial Transplant 2004; 19:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16442/abstract/7\">",
"      Dugu&eacute; AE, Levesque SP, Fischer MO, et al. Vascular access sites for acute renal replacement in intensive care units. Clin J Am Soc Nephrol 2012; 7:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16442/abstract/8\">",
"      Vascular Access 2006 Work Group. Clinical practice guidelines for vascular access. Am J Kidney Dis 2006; 48 Suppl 1:S176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16442/abstract/9\">",
"      Oliver MJ, Callery SM, Thorpe KE, et al. Risk of bacteremia from temporary hemodialysis catheters by site of insertion and duration of use: a prospective study. Kidney Int 2000; 58:2543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16442/abstract/10\">",
"      Weijmer MC, Vervloet MG, ter Wee PM. Prospective follow-up of a novel design haemodialysis catheter; lower infection rates and improved survival. Nephrol Dial Transplant 2008; 23:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16442/abstract/11\">",
"      Schwab SJ, Beathard G. The hemodialysis catheter conundrum: hate living with them, but can't live without them. Kidney Int 1999; 56:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16442/abstract/12\">",
"      Coryell L, Lott JP, Stavropoulos SW, et al. The case for primary placement of tunneled hemodialysis catheters in acute kidney injury. J Vasc Interv Radiol 2009; 20:1578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16442/abstract/13\">",
"      III. NKF-K/DOQI Clinical Practice Guidelines for Vascular Access: update 2000. Am J Kidney Dis 2001; 37:S137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16442/abstract/14\">",
"      Parienti JJ, M&eacute;garbane B, Fischer MO, et al. Catheter dysfunction and dialysis performance according to vascular access among 736 critically ill adults requiring renal replacement therapy: a randomized controlled study. Crit Care Med 2010; 38:1118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16442/abstract/15\">",
"      Ash SR. Advances in tunneled central venous catheters for dialysis: design and performance. Semin Dial 2008; 21:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16442/abstract/16\">",
"      Hockenhull JC, Dwan KM, Smith GW, et al. The clinical effectiveness of central venous catheters treated with anti-infective agents in preventing catheter-related bloodstream infections: a systematic review. Crit Care Med 2009; 37:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16442/abstract/17\">",
"      Chatzinikolaou I, Finkel K, Hanna H, et al. Antibiotic-coated hemodialysis catheters for the prevention of vascular catheter-related infections: a prospective, randomized study. Am J Med 2003; 115:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16442/abstract/18\">",
"      Bleyer AJ, Mason L, Russell G, et al. A randomized, controlled trial of a new vascular catheter flush solution (minocycline-EDTA) in temporary hemodialysis access. Infect Control Hosp Epidemiol 2005; 26:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16442/abstract/19\">",
"      Dwyer A. Surface-treated catheters--a review. Semin Dial 2008; 21:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16442/abstract/20\">",
"      Trerotola SO, Johnson MS, Shah H, et al. Tunneled hemodialysis catheters: use of a silver-coated catheter for prevention of infection--a randomized study. Radiology 1998; 207:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16442/abstract/21\">",
"      Alderman RL, Sugarbaker PH. Prospective nonrandomized trial of silver impregnated cuff central lines. Int Surg 2005; 90:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16442/abstract/22\">",
"      Jain G, Allon M, Saddekni S, et al. Does heparin coating improve patency or reduce infection of tunneled dialysis catheters? Clin J Am Soc Nephrol 2009; 4:1787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16442/abstract/23\">",
"      Clark TW, Jacobs D, Charles HW, et al. Comparison of heparin-coated and conventional split-tip hemodialysis catheters. Cardiovasc Intervent Radiol 2009; 32:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16442/abstract/24\">",
"      Bridges C. New heparin coating reduces thrombosis and fibrin sheath formation in HD catheters. Nephrol News Issues 2007; 21:32, 34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16442/abstract/25\">",
"      Hodges TC, Fillinger MF, Zwolak RM, et al. Longitudinal comparison of dialysis access methods: risk factors for failure. J Vasc Surg 1997; 26:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16442/abstract/26\">",
"      Tesio F, De Baz H, Panarello G, et al. Double catheterization of the internal jugular vein for hemodialysis: indications, techniques, and clinical results. Artif Organs 1994; 18:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16442/abstract/27\">",
"      Lund GB, Trerotola SO, Scheel PF Jr, et al. Outcome of tunneled hemodialysis catheters placed by radiologists. Radiology 1996; 198:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16442/abstract/28\">",
"      Mosquera DA, Gibson SP, Goldman MD. Vascular access surgery: a 2-year study and comparison with the Permcath. Nephrol Dial Transplant 1992; 7:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16442/abstract/29\">",
"      Duncan ND, Singh S, Cairns TD, et al. Tesio-Caths provide effective and safe long-term vascular access. Nephrol Dial Transplant 2004; 19:2816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16442/abstract/30\">",
"      Suhocki PV, Conlon PJ Jr, Knelson MH, et al. Silastic cuffed catheters for hemodialysis vascular access: thrombolytic and mechanical correction of malfunction. Am J Kidney Dis 1996; 28:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16442/abstract/31\">",
"      Atherikul K, Schwab SJ, Conlon PJ. Adequacy of haemodialysis with cuffed central-vein catheters. Nephrol Dial Transplant 1998; 13:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16442/abstract/32\">",
"      Depner TA. Catheter performance. Semin Dial 2001; 14:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16442/abstract/33\">",
"      Richardson AI 2nd, Leake A, Schmieder GC, et al. Should fistulas really be first in the elderly patient? J Vasc Access 2009; 10:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16442/abstract/34\">",
"      Ocak G, Halbesma N, le Cessie S, et al. Haemodialysis catheters increase mortality as compared to arteriovenous accesses especially in elderly patients. Nephrol Dial Transplant 2011; 26:2611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16442/abstract/35\">",
"      Verdalles U, Abad S, Aragoncillo I, et al. Factors predicting mortality in elderly patients on dialysis. Nephron Clin Pract 2010; 115:c28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16442/abstract/36\">",
"      McGee DC, Gould MK. Preventing complications of central venous catheterization. N Engl J Med 2003; 348:1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16442/abstract/37\">",
"      Fan PY, Schwab SJ. Vascular access: concepts for the 1990s. J Am Soc Nephrol 1992; 3:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16442/abstract/38\">",
"      Bander, SJ, Schwab, SJ. Central venous angioaccess for hemodialysis and its complications. Semin Dial 1992; 5:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16442/abstract/39\">",
"      K/DOQI Clinical Practice Guidelines and Clinical Practice Recommendations 2006 Updates Hemodialysis adequacy Peritoneal Dialysis Adequacy Vascular Access. Am J Kidney Dis 2006; 48(Suppl 1):S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16442/abstract/40\">",
"      Hern&aacute;ndez D, D&iacute;az F, Rufino M, et al. Subclavian vascular access stenosis in dialysis patients: natural history and risk factors. J Am Soc Nephrol 1998; 9:1507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16442/abstract/41\">",
"      Silberzweig JE, Sacks D, Khorsandi AS, et al. Reporting standards for central venous access. J Vasc Interv Radiol 2003; 14:S443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16442/abstract/42\">",
"      Maya ID, Allon M. Outcomes of tunneled femoral hemodialysis catheters: comparison with internal jugular vein catheters. Kidney Int 2005; 68:2886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16442/abstract/43\">",
"      Little MA, Conlon PJ, Walshe JJ. Access recirculation in temporary hemodialysis catheters as measured by the saline dilution technique. Am J Kidney Dis 2000; 36:1135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16442/abstract/44\">",
"      Frampton AE, Kessaris N, Hossain M, et al. Use of the femoral artery route for placement of temporary catheters for emergency haemodialysis when all usual central venous access sites are exhausted. Nephrol Dial Transplant 2009; 24:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16442/abstract/45\">",
"      George A, Tokars JI, Clutterbuck EJ, et al. Reducing dialysis associated bacteraemia, and recommendations for surveillance in the United Kingdom: prospective study. BMJ 2006; 332:1435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16442/abstract/46\">",
"      Geddes CC, Walbaum D, Fox JG, Mactier RA. Insertion of internal jugular temporary hemodialysis cannulae by direct ultrasound guidance--a prospective comparison of experienced and inexperienced operators. Clin Nephrol 1998; 50:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16442/abstract/47\">",
"      Keenan SP. Use of ultrasound to place central lines. J Crit Care 2002; 17:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16442/abstract/48\">",
"      Skolnick ML. The role of sonography in the placement and management of jugular and subclavian central venous catheters. AJR Am J Roentgenol 1994; 163:291.",
"     </a>",
"    </li>",
"    <li>",
"     National Institute for Clinical Excellence. Guidance on the use of ultrasound locating  devices for placing central venous catheters. 2005. file://www.nice.org.uk/nicemedia/live/11474/32461/32461.pdf (Accessed on December 12, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16442/abstract/50\">",
"      Kwon TH, Kim YL, Cho DK. Ultrasound-guided cannulation of the femoral vein for acute haemodialysis access. Nephrol Dial Transplant 1997; 12:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16442/abstract/51\">",
"      Kumwenda MJ. Two different techniques and outcomes for insertion of long-term tunnelled haemodialysis catheters. Nephrol Dial Transplant 1997; 12:1013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16442/abstract/52\">",
"      Lin BS, Huang TP, Tang GJ, et al. Ultrasound-guided cannulation of the internal jugular vein for dialysis vascular access in uremic patients. Nephron 1998; 78:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16442/abstract/53\">",
"      Prabhu MV, Juneja D, Gopal PB, et al. Ultrasound-guided femoral dialysis access placement: a single-center randomized trial. Clin J Am Soc Nephrol 2010; 5:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16442/abstract/54\">",
"      Rabindranath KS, Kumar E, Shail R, Vaux EC. Ultrasound use for the placement of haemodialysis catheters. Cochrane Database Syst Rev 2011; :CD005279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16442/abstract/55\">",
"      Headley CM, Thompson CL, Carter M, et al. The role of real-time ultrasound and physical examination measurements in placement of cuffed-tunneled hemodialysis catheters. Nephrol Nurs J 2004; 31:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16442/abstract/56\">",
"      Oran NT, Eser I. Impact of heparin locking frequency on preventing temporary dialysis catheter dysfunction in haemodialysis patients. J Ren Care 2008; 34:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16442/abstract/57\">",
"      Niyyar VD. Catheter dysfunction: the role of lock solutions. Semin Dial 2012; 25:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16442/abstract/58\">",
"      Moran JE, Ash SR, ASDIN Clinical Practice Committee. Locking solutions for hemodialysis catheters; heparin and citrate--a position paper by ASDIN. Semin Dial 2008; 21:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16442/abstract/59\">",
"      Schwab SJ, Buller GL, McCann RL, et al. Prospective evaluation of a Dacron cuffed hemodialysis catheter for prolonged use. Am J Kidney Dis 1988; 11:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16442/abstract/60\">",
"      Grudzinski L, Quinan P, Kwok S, Pierratos A. Sodium citrate 4% locking solution for central venous dialysis catheters--an effective, more cost-efficient alternative to heparin. Nephrol Dial Transplant 2007; 22:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16442/abstract/61\">",
"      Lok CE, Appleton D, Bhola C, et al. Trisodium citrate 4%--an alternative to heparin capping of haemodialysis catheters. Nephrol Dial Transplant 2007; 22:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16442/abstract/62\">",
"      Schenk P, Rosenkranz AR, W&ouml;lfl G, et al. Recombinant tissue plasminogen activator is a useful alternative to heparin in priming quinton permcath. Am J Kidney Dis 2000; 35:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16442/abstract/63\">",
"      Gittins NS, Hunter-Blair YL, Matthews JN, Coulthard MG. Comparison of alteplase and heparin in maintaining the patency of paediatric central venous haemodialysis lines: a randomised controlled trial. Arch Dis Child 2007; 92:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16442/abstract/64\">",
"      Hemmelgarn BR, Moist LM, Lok CE, et al. Prevention of dialysis catheter malfunction with recombinant tissue plasminogen activator. N Engl J Med 2011; 364:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16442/abstract/65\">",
"      Allon M. Dialysis catheters and recombinant tissue plasminogen activator. N Engl J Med 2011; 364:1779; author reply 1779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16442/abstract/66\">",
"      Mokrzyck H, Rush H, Jean-Jerome K, et al. Mini dose warfarin for the prevention of tunneled cuff thrombosis. J Am Soc Nephrol 1999; 10:1082.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16442/abstract/67\">",
"      Liangos O, Gul A, Madias NE, Jaber BL. Long-term management of the tunneled venous catheter. Semin Dial 2006; 19:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16442/abstract/68\">",
"      Raja RM, Fernandes M, Kramer MS, et al. Comparison of subclavian vein with femoral vein catheterization for hemodialysis. Am J Kidney Dis 1983; 2:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16442/abstract/69\">",
"      Hemodialysis Clinical Practice Guidelines for the Canadian Society of Nephrology. J Am Soc Nephrol 2006; 17(Suppl 1):S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16442/abstract/70\">",
"      Dunn J, Nylander W, Richie R. Central venous dialysis access: experience with a dual-lumen, silicone rubber catheter. Surgery 1987; 102:784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16442/abstract/71\">",
"      Oliver MJ, Mendelssohn DC, Quinn RR, et al. Catheter patency and function after catheter sheath disruption: a pilot study. Clin J Am Soc Nephrol 2007; 2:1201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16442/abstract/72\">",
"      Daeihagh P, Jordan J, Chen J, Rocco M. Efficacy of tissue plasminogen activator administration on patency of hemodialysis access catheters. Am J Kidney Dis 2000; 36:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16442/abstract/73\">",
"      Schwab SJ, Quarles LD, Middleton JP, et al. Hemodialysis-associated subclavian vein stenosis. Kidney Int 1988; 33:1156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16442/abstract/74\">",
"      Oguzkurt L, Tercan F, Torun D, et al. Impact of short-term hemodialysis catheters on the central veins: a catheter venographic study. Eur J Radiol 2004; 52:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16442/abstract/75\">",
"      Cimochowski GE, Worley E, Rutherford WE, et al. Superiority of the internal jugular over the subclavian access for temporary dialysis. Nephron 1990; 54:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16442/abstract/76\">",
"      Schillinger F, Schillinger D, Montagnac R, Milcent T. Post catheterisation vein stenosis in haemodialysis: comparative angiographic study of 50 subclavian and 50 internal jugular accesses. Nephrol Dial Transplant 1991; 6:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16442/abstract/77\">",
"      NKF-DOQI Clinical Practice Guidelines for Vascular Access. VI. Acute hemodialysis vascular access &mdash; Noncuffed catheters. Am J Kidney Dis 2001; 37(Suppl 1):S146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16442/abstract/78\">",
"      NKF-DOQI clinical practice guidelines for vascular access. National Kidney Foundation-Dialysis Outcomes Quality Initiative. Am J Kidney Dis 1997; 30:S150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16442/abstract/79\">",
"      Newman GE, Saeed M, Himmelstein S, et al. Total central vein obstruction: resolution with angioplasty and fibrinolysis. Kidney Int 1991; 39:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16442/abstract/80\">",
"      Saad TF. Bacteremia associated with tunneled, cuffed hemodialysis catheters. Am J Kidney Dis 1999; 34:1114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16442/abstract/81\">",
"      Marr KA, Sexton DJ, Conlon PJ, et al. Catheter-related bacteremia and outcome of attempted catheter salvage in patients undergoing hemodialysis. Ann Intern Med 1997; 127:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16442/abstract/82\">",
"      Dahlberg PJ, Yutuc WR, Newcomer KL. Subclavian hemodialysis catheter infections. Am J Kidney Dis 1986; 7:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16442/abstract/83\">",
"      Nielsen J, Ladefoged SD, Kolmos HJ. Dialysis catheter-related septicaemia--focus on Staphylococcus aureus septicaemia. Nephrol Dial Transplant 1998; 13:2847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16442/abstract/84\">",
"      Kairaitis LK, Gottlieb T. Outcome and complications of temporary haemodialysis catheters. Nephrol Dial Transplant 1999; 14:1710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16442/abstract/85\">",
"      Parienti JJ, Thirion M, M&eacute;garbane B, et al. Femoral vs jugular venous catheterization and risk of nosocomial events in adults requiring acute renal replacement therapy: a randomized controlled trial. JAMA 2008; 299:2413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/3/16442/abstract/86\">",
"      Ishani A, Collins AJ, Herzog CA, Foley RN. Septicemia, access and cardiovascular disease in dialysis patients: the USRDS Wave 2 study. Kidney Int 2005; 68:311.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1843 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-EC2EE36D8B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_3_16442=[""].join("\n");
var outline_f16_3_16442=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9380285\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H79680952\">",
"      DIALYSIS CATHETERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H79682271\">",
"      Basic principles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Non-tunneled catheters",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H79683463\">",
"      - Duration of use",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Tunneled catheters",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H79683881\">",
"      - Surface-coated catheters",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1037144934\">",
"      - Catheter life",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H791616603\">",
"      LONG-TERM CATHETERS VERSUS ARTERIOVENOUS ACCESS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H79681577\">",
"      CATHETER PLACEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H79681682\">",
"      Access site considerations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H79681689\">",
"      Technique",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H79681696\">",
"      - Ultrasound guidance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H79682089\">",
"      - Catheter positioning",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H79683083\">",
"      Anticoagulants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      DIALYSIS CATHETER COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Insertion or immediate access-related",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H79683300\">",
"      Catheter malfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Central vein stenosis/thrombosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Catheter infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9380285\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/1843\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/1843|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/21/42324\" title=\"figure 1\">",
"      Anatomy SC IJ central line",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/48/38664?source=related_link\">",
"      Air embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/26/27050?source=related_link\">",
"      Catheter-induced upper extremity venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/1/29?source=related_link\">",
"      Complications of central venous catheters and their prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/14/38120?source=related_link\">",
"      Hemodialysis anticoagulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/32/44553?source=related_link\">",
"      Overview of central venous access",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/37/18010?source=related_link\">",
"      Percutaneous angioplasty for the treatment of venous stenosis affecting hemodialysis access grafts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/11/36024?source=related_link\">",
"      Placement of femoral venous catheters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/14/3306?source=related_link\">",
"      Placement of jugular venous catheters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/27/1466?source=related_link\">",
"      Placement of subclavian venous catheters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/53/31578?source=related_link\">",
"      Prevention of intravascular catheter-related infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/47/3833?source=related_link\">",
"      Principles of ultrasound-guided venous access",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/48/7942?source=related_link\">",
"      Strategies other than treatment of stenosis to prevent thrombosis of hemodialysis vascular access grafts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/22/15722?source=related_link\">",
"      Thrombosis associated with chronic hemodialysis vascular access: Catheters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/8/29834?source=related_link\">",
"      Tunneled, cuffed hemodialysis catheter-related bacteremia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_3_16443="Biliary disorders evaluated by ERCP";
var content_f16_3_16443=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F64323&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F64323&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Biliary disorders in children in which ERCP can be helpful",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Congenital",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Biliary atresia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Alagille syndrome*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Caroli disease*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Biliary cysts",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Biliary strictures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Acquired",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sclerosing cholangitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ascariasis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Choledocholithiasis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bile plug syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Malignant biliary strictures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Common bile duct complications after liver transplantation",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ERCP: endoscopic retrograde cholangiopancreatography.",
"     <br>",
"      * ERCP is not generally needed for diagnosis of this disorder.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_3_16443=[""].join("\n");
var outline_f16_3_16443=null;
var title_f16_3_16444="Dose modif neurotox oxaliplatin";
var content_f16_3_16444=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F57185&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F57185&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Dose modifications for neurotoxicity in patients receiving oxaliplatin 85 mg/m",
"    <sup>",
"     2",
"    </sup>",
"    every two weeks*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Type/duration of neurotoxicity",
"       </td>",
"       <td class=\"subtitle1\">",
"        Transient (&lt;7 days)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Nonpersistent (&gt;7 days but &lt;14 days)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Persistent between courses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cold-related dysesthesia",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        None",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Paresthesias (mild)",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        None",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Paresthesias associated with pain or complaint",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        None",
"       </td>",
"       <td>",
"        Normal examination: reduce to 75 mg/m",
"        <sup>",
"         2",
"        </sup>",
"       </td>",
"       <td>",
"        Stop until improvement/recovery.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Abnormal examination: omit one cycle oxaliplatin, then restart at 75 mg/m",
"        <sup>",
"         2",
"        </sup>",
"       </td>",
"       <td>",
"        If improvement/recovery, restart at 75 mg/m",
"        <sup>",
"         2",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Paresthesias associated with functional impairment",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        None",
"       </td>",
"       <td>",
"        Normal examination and not interfering with activities of daily living: reduce to 75 mg/m",
"        <sup>",
"         2",
"        </sup>",
"       </td>",
"       <td>",
"        Stop until improvement/recovery.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Abnormal examination or interfering with activities of daily living: omit one cycle oxaliplatin, then restart at 75 mg/m",
"        <sup>",
"         2",
"        </sup>",
"       </td>",
"       <td>",
"        If improvement/recovery, restart at 75 mg/m",
"        <sup>",
"         2",
"        </sup>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * For patients on oxaliplatin 130 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every three weeks, the dose should be reduced to 100 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     .",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Gamelin, E, Gamelin, L, Bossi, L, Quasthoff. Clinical aspects and molecular basis of oxaliplatin neurotoxicity: Current management and development of preventive measures. Semin Oncol 2002: (suppl 15) 29:25.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_3_16444=[""].join("\n");
var outline_f16_3_16444=null;
var title_f16_3_16445="CMT types 4 through 7";
var content_f16_3_16445=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F52711&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F52711&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical features of CMT4, CMT5, CMT6, and CMT7",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Disorder",
"       </td>",
"       <td class=\"subtitle1\">",
"        Gene",
"       </td>",
"       <td class=\"subtitle1\">",
"        Chromosome",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical features",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        CMT4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        CMT4A",
"       </td>",
"       <td>",
"        GDAP1",
"       </td>",
"       <td>",
"        8q13-q21.1",
"       </td>",
"       <td>",
"        <p>",
"         Onset in early childhood",
"        </p>",
"        <p>",
"         Distal weakness",
"        </p>",
"        <p>",
"         Mild sensory loss",
"        </p>",
"        <p>",
"         Rapidly progressive",
"        </p>",
"        <p>",
"         Incapacity in first decade",
"        </p>",
"        <p>",
"         NCV moderately reduced",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        CMT4B1",
"       </td>",
"       <td>",
"        MTMR2",
"       </td>",
"       <td>",
"        11q22-23",
"       </td>",
"       <td>",
"        <p>",
"         Onset at age 2 to 4 years",
"        </p>",
"        <p>",
"         Distal and proximal weakness",
"        </p>",
"        <p>",
"         Moderate sensory loss",
"        </p>",
"        <p>",
"         Frequent involvement of cranial nerves",
"        </p>",
"        <p>",
"         NCV slowed",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        CMT4B2",
"       </td>",
"       <td>",
"        CMT4B2",
"       </td>",
"       <td>",
"        11p15",
"       </td>",
"       <td>",
"        <p>",
"         Onset in first two decades",
"        </p>",
"        <p>",
"         Initial distal weakness",
"        </p>",
"        <p>",
"         Proximal weakness after several years",
"        </p>",
"        <p>",
"         NCV slowed",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        CMT4C",
"       </td>",
"       <td>",
"        SH3TC2",
"       </td>",
"       <td>",
"        5q32",
"       </td>",
"       <td>",
"        <p>",
"         Severe spinal deformities and weakness",
"        </p>",
"        <p>",
"         Onset in childhood and adolescence",
"        </p>",
"        <p>",
"         NCV slowed",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        CMT4D",
"       </td>",
"       <td>",
"        NDRG1",
"       </td>",
"       <td>",
"        8q24.3",
"       </td>",
"       <td>",
"        <p>",
"         Early onset neuropathy",
"        </p>",
"        <p>",
"         Muscle weakness and wasting",
"        </p>",
"        <p>",
"         Skeletal deformities",
"        </p>",
"        <p>",
"         Sensory loss",
"        </p>",
"        <p>",
"         Neural deafness in second or third decade",
"        </p>",
"        <p>",
"         NCV severely reduced",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        CMT4E",
"       </td>",
"       <td>",
"        EGR2",
"       </td>",
"       <td>",
"        10q21.1-22.1",
"       </td>",
"       <td>",
"        Distal weakness at birth",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        CMT4F",
"       </td>",
"       <td>",
"        PRX",
"       </td>",
"       <td>",
"        19q13.1-13.2",
"       </td>",
"       <td>",
"        <p>",
"         Onset in early childhood",
"        </p>",
"        <p>",
"         Distal muscle weakness",
"        </p>",
"        <p>",
"         Severe sensory loss",
"        </p>",
"        <p>",
"         Absent sensory and motor evoked response on NCV",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        CMT4H",
"       </td>",
"       <td>",
"        FGD4",
"       </td>",
"       <td>",
"        12p11.2",
"       </td>",
"       <td>",
"        <p>",
"         Severe demyelinating neuropathy",
"        </p>",
"        <p>",
"         Unsteady gait",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        CMT4J",
"       </td>",
"       <td>",
"        FIG4",
"       </td>",
"       <td>",
"        6q21",
"       </td>",
"       <td>",
"        <p>",
"         Childhood or adult onset",
"        </p>",
"        <p>",
"         Widespread denervation",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         CMT5",
"        </strong>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        <p>",
"         Spastic paraparesis",
"        </p>",
"        <p>",
"         Sensory neuropathy",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         CTM6",
"        </strong>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        <p>",
"         Optic atrophy",
"        </p>",
"        <p>",
"         Motor sensory neuropathy",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         CMT7",
"        </strong>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        <p>",
"         Retinitis pigmentosa",
"        </p>",
"        <p>",
"         Motor sensory neuropathy",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_3_16445=[""].join("\n");
var outline_f16_3_16445=null;
var title_f16_3_16446="Chromosome 13 in myeloma";
var content_f16_3_16446=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F64638&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F64638&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Chromosome 13 deletions in multiple myeloma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 331px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Conventional cytogenetic analysis with G banding was performed in 106 patients with multiple myeloma. Each vertical line to the right of the figure (the long arm of chromosome 13) indicates the part of chromosome 13 that was found to be deleted in one patient. With the exception of eight patients, the minimal region of deletion overlap appears to be in the 13q14 region (red arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with permission from Shaughnessy, J, et al. Blood 2000; 96:1505. Copyright 2000, American Society of Hematology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_3_16446=[""].join("\n");
var outline_f16_3_16446=null;
var title_f16_3_16447="VE VO2 pregnancy exercise";
var content_f16_3_16447=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F65817&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F65817&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 599px\">",
"   <div class=\"ttl\">",
"    Ventilatory equivalent (VE/VO",
"    <sub>",
"     2",
"    </sub>",
"    ) determinations done before and during symptom-limited maximal oxygen consumption exercise",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 579px; height: 445px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The",
"    <strong>",
"     solid line",
"    </strong>",
"    illustrates the mean values for the pregnant subjects and the",
"    <strong>",
"     dashed line",
"    </strong>",
"    the nonpregnant control subjects.",
"    <div class=\"footnotes\">",
"     TM=treadmill, MPH=miles per hour",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Artal, R, Wiswell, R, Romen, Y, Dorey, F. Pulmonary responses to exercise in pregnancy. Am J Obstet Gynecol 1986; 154:378. Copyright &copy;1986 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_3_16447=[""].join("\n");
var outline_f16_3_16447=null;
